<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006044</article-id><article-id pub-id-type="pmc">PMC11859375</article-id><article-id pub-id-type="doi">10.3390/ph18020232</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Naringenin-Loaded Solid Lipid Nanoparticles: Physical&#x02013;Chemical Characterization and In Vitro Antibacterial Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9638-5520</contrib-id><name><surname>De Gaetano</surname><given-names>Federica</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00232" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3562-6244</contrib-id><name><surname>Caridi</surname><given-names>Francesco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceuticals-18-00232" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Totaro</surname><given-names>Noemi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1393-477X</contrib-id><name><surname>Celesti</surname><given-names>Consuelo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceuticals-18-00232" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2907-9165</contrib-id><name><surname>Venuti</surname><given-names>Valentina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceuticals-18-00232" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ginestra</surname><given-names>Giovanna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4280-7895</contrib-id><name><surname>Nostro</surname><given-names>Antonia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Tommasini</surname><given-names>Silvana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8743-2046</contrib-id><name><surname>Ventura</surname><given-names>Cinzia Anna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00232" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8670-7685</contrib-id><name><surname>Stancanelli</surname><given-names>Rosanna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00232" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Fan</surname><given-names>Kelong</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00232"><label>1</label>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, V.le Ferdinando Stagno D&#x02019;Alcontres 31, 98166 Messina, Italy; <email>noemi.totaro@studenti.unime.it</email> (N.T.); <email>giovanna.ginestra@unime.it</email> (G.G.); <email>antonia.nostro@unime.it</email> (A.N.); <email>stommasini@unime.it</email> (S.T.); <email>rstancanelli@unime.it</email> (R.S.)</aff><aff id="af2-pharmaceuticals-18-00232"><label>2</label>Department of Mathematical and Computer Sciences, Physical Sciences and Earth Sciences, University of Messina, V.le Ferdinando Stagno D&#x02019;Alcontres 31, 98166 Messina, Italy; <email>fcaridi@unime.it</email> (F.C.); <email>vvenuti@unime.it</email> (V.V.)</aff><aff id="af3-pharmaceuticals-18-00232"><label>3</label>Department of Engineering, University of Messina, Contrada Di Dio, 98166 Messina, Italy; <email>ccelesti@unime.it</email></aff><author-notes><corresp id="c1-pharmaceuticals-18-00232"><label>*</label>Correspondence: <email>fedegaetano@unime.it</email> (F.D.G.); <email>caventura@unime.it</email> (C.A.V.)</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>232</elocation-id><history><date date-type="received"><day>16</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Currently, problems related to antibiotic resistance are shifting the focus of pharmaceutical research towards natural molecules with antibacterial properties. Among them, flavonoids represent promising molecules with strong antibacterial features; however, they have poor biopharmaceutical properties. In this study, we developed solid lipid nanoparticles (SLNs) loaded with the flavanone naringenin (NRG) to offer an option for treating bacterial infections. NRG-SLNs systems were prepared by a solvent emulsification/diffusion and ultrasonication method, using Compritol<sup>&#x000ae;</sup> 888 ATO (COM) as the lipid. The optimal formulation was obtained using a 10% (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) theoretical amount of NRG (NRG<sub>10</sub>-SLNs), exhibiting homogeneous sizes (approximately 50 nm and 0.15 polydispersity index), negative zeta potential (&#x02212;30 mV), and excellent encapsulation parameters (an encapsulation efficiency percentage of 97.9% and a drug content of 4%). NRG<sub>10</sub>-SLNs presented good physical stability over 4 weeks. A cumulative drug release of 55% in 24 h and the prolonged release of the remaining amount over 10 days was observed. In addition, &#x000b5;-Raman spectroscopy, differential scanning calorimetry, thermogravimetric analysis, and X-ray diffraction measurements were carried out to characterize the drug&#x02013;lipid interactions. Finally, the in vitro antibacterial and antibiofilm activities of NRG<sub>10</sub>-SLNs were assayed and compared to free NRG. NRG<sub>10</sub>-SLNs were bacteriostatic against <italic toggle="yes">Staphylococcus aureus,</italic> including the methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) and <italic toggle="yes">Escherichia coli</italic> strains. An improvement in the antibacterial activity of NRG-loaded SLNs compared to the free molecule was observed against <italic toggle="yes">S. aureus</italic> strains, probably due to the interaction of the surfactant-coated SLNs with the bacterial surface. A similar trend was observed for the biofilm inhibition.</p></abstract><kwd-group><kwd>naringenin</kwd><kwd>solid lipid nanoparticles</kwd><kwd>technological characterization</kwd><kwd>physical&#x02013;chemical characterization</kwd><kwd>in vitro antibacterial activity</kwd><kwd>biofilm inhibition</kwd></kwd-group><funding-group><award-group><funding-source>European Union (NextGeneration EU)</funding-source><award-id>ECS00000022</award-id></award-group><funding-statement>This work has been partially funded by the European Union (NextGeneration EU) through the MUR-PNRR project SAMOTHRACE (ECS00000022).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00232"><title>1. Introduction</title><p>Over the years, the increasing use of antibiotics in medicine has given rise to the ever-growing problem of antimicrobial resistance, which is equally alarming during both hospital and non-hospital treatment. Consequently, there is an increasing need to develop new therapeutic strategies with the ability to circumvent bacterial resistance. In this context, natural antimicrobial agents are considered a promising approach in counteracting the spread of difficult-to-treat microorganisms [<xref rid="B1-pharmaceuticals-18-00232" ref-type="bibr">1</xref>]. Among them, flavonoids are a group of bioactive molecules derived from plants, with their antibacterial activity being widely recognized in the literature [<xref rid="B2-pharmaceuticals-18-00232" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00232" ref-type="bibr">3</xref>]. Due to their natural origins, flavonoids attain a higher consumer compliance than chemically synthesized drugs. Moreover, they have an advantage over antibiotics due to their multiple actions on cells, meaning that it is less likely that bacteria will develop resistance to them [<xref rid="B4-pharmaceuticals-18-00232" ref-type="bibr">4</xref>]. Specifically, studies suggest that the antibacterial activity of flavonoids occurs through different mechanisms: (i) inhibition of nucleic acid synthesis, (ii) inhibition of cytoplasmic membrane function, and (iii) inhibition of energy metabolism [<xref rid="B2-pharmaceuticals-18-00232" ref-type="bibr">2</xref>]. Furthermore, flavonoids are relatively non-toxic, low cost, and readily available.</p><p>Naringenin (5,7,4&#x02032;-trihydroxy flavanone; NRG) (<xref rid="app1-pharmaceuticals-18-00232" ref-type="app">Figure S1</xref>) is an aglycone belonging to a group of flavanones that have demonstrated interesting pharmacological effects on biological systems, including anti-inflammatory, anticancer, and antioxidant activity [<xref rid="B5-pharmaceuticals-18-00232" ref-type="bibr">5</xref>]. NRG also shows interesting antimicrobial activity against a variety of bacteria [<xref rid="B6-pharmaceuticals-18-00232" ref-type="bibr">6</xref>], such as <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Streptococcus mutans,</italic> and pathogenic multidrug-resistant bacteria such as methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) [<xref rid="B7-pharmaceuticals-18-00232" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00232" ref-type="bibr">8</xref>]. The activity of NRG is stronger against Gram-positive than Gram-negative bacteria, as demonstrated by Wang et al. [<xref rid="B9-pharmaceuticals-18-00232" ref-type="bibr">9</xref>] in a comparative study of NRG activity against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">E. coli</italic>. NRG caused a dose-dependent growth rate inhibition, which was higher in <italic toggle="yes">S. aureus</italic> than in <italic toggle="yes">E. coli.</italic> It appears that low concentrations of NRG produced variations in the membrane protein conformation and fatty acid composition, disrupting the <italic toggle="yes">S. aureus</italic> biofilm, whilst at high concentrations, NRG significantly improved membrane fluidity in the bacteria [<xref rid="B9-pharmaceuticals-18-00232" ref-type="bibr">9</xref>]. Furthermore, NRG can bind to <italic toggle="yes">S. aureus</italic> DNA and can inhibit quorum sensing, thus limiting biofilm formation [<xref rid="B7-pharmaceuticals-18-00232" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceuticals-18-00232" ref-type="bibr">9</xref>]. NRG could modify the signaling mediated by AI-2 (population-sensing signaling molecule), produced by intestinal flora and involved in the communication between various bacterial species [<xref rid="B10-pharmaceuticals-18-00232" ref-type="bibr">10</xref>]. NRG is also active against <italic toggle="yes">S. mutans,</italic> inducing the total inhibition of biofilm formation at a dose of 200 &#x003bc;g/mL. The study demonstrated that NRG is able to improve the surface hydrophobicity of the bacteria and decrease aggregation [<xref rid="B11-pharmaceuticals-18-00232" ref-type="bibr">11</xref>]. Another interesting NRG activity is the inhibition of the &#x003b1;-toxin produced by different <italic toggle="yes">S. aureus</italic> strains, which was evaluated by measuring the reduction in hemolytic activity with respect to the control. Zhang et al. demonstrated that, in mice infected with the <italic toggle="yes">S. aureus</italic> strain that causes pneumonia, a significant reduction in the inflammation area was achieved after treatment with 100 &#x003bc;g/Kg of NRG, when compared to the non-treated animals [<xref rid="B12-pharmaceuticals-18-00232" ref-type="bibr">12</xref>]. This effect was probably due to a reduction in pro-inflammatory cytokines, as demonstrated in a study involving pediatric patients with bronchial pneumonia. The authors demonstrated that treatment with NRG decreased IL-6, IL-8, and TNF-&#x003b1; levels, whilst increasing the amount of anti-inflammatory IL-10 [<xref rid="B13-pharmaceuticals-18-00232" ref-type="bibr">13</xref>].</p><p>It is evident that NRG implements different mechanisms against Gram-positive bacteria, thus its development as an antibacterial drug could represent a key factor in overcoming antibiotic resistance. Unfortunately, NRG possesses low water solubility (4.38 &#x003bc;g/mL) [<xref rid="B14-pharmaceuticals-18-00232" ref-type="bibr">14</xref>], intestinal instability, and extensive first-pass metabolism, which negatively affects its oral bioavailability (only 15% of ingested NRG is absorbed in the human gastrointestinal tract) [<xref rid="B15-pharmaceuticals-18-00232" ref-type="bibr">15</xref>], limiting its clinical application. New formulative strategies are needed to overcome these drawbacks, improving solubility, stability, and bioavailability, and permitting the controlled release of NRG [<xref rid="B16-pharmaceuticals-18-00232" ref-type="bibr">16</xref>] in the treatment of various pathologies. Complexation or conjugation with cyclodextrins (CDs) represents an excellent strategy to improve the water solubility of both synthetic drugs [<xref rid="B17-pharmaceuticals-18-00232" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00232" ref-type="bibr">18</xref>] and natural compounds [<xref rid="B19-pharmaceuticals-18-00232" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00232" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-18-00232" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00232" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00232" ref-type="bibr">23</xref>]. For example, native and modified &#x003b2;-CD improved NRG hydrophilicity [<xref rid="B24-pharmaceuticals-18-00232" ref-type="bibr">24</xref>], particularly when complexation was combined with a controlled pH and the presence of polysorbate [<xref rid="B25-pharmaceuticals-18-00232" ref-type="bibr">25</xref>]. Furthermore, the complexation increased NRG permeation through the Caco-2 monolayer and improved its oral bioavailability (approximately 7-fold and 15-fold for AUC and Cmax, respectively), representing a suitable option for the development of NRG as a therapeutic agent in the treatment of dyslipidemia, diabetes, and HCV infection [<xref rid="B26-pharmaceuticals-18-00232" ref-type="bibr">26</xref>]. Polymeric nanoparticles also possess interesting properties in delivering both synthetic [<xref rid="B27-pharmaceuticals-18-00232" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00232" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-18-00232" ref-type="bibr">29</xref>] and natural compounds [<xref rid="B30-pharmaceuticals-18-00232" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00232" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00232" ref-type="bibr">32</xref>]. Polymeric NRG nanoformulations with increased NRG bioavailability and effectiveness in different pathologies have been developed. Hybrid Chitosan/&#x003b2;-CD nanoparticles potentiated the antibacterial and antibiofilm activities of NRG, achieving ~34% growth inhibition and ~60% biofilm inhibition towards the biosensor <italic toggle="yes">E. coli</italic> Top 10 strain [<xref rid="B33-pharmaceuticals-18-00232" ref-type="bibr">33</xref>]. NRG-loaded PLGA nanoparticles for nose-to-brain delivery were able to prevent neurodegeneration induced by Paraquat in an in vivo model of Parkinson&#x02019;s disease by regulating oxidative stress markers [<xref rid="B34-pharmaceuticals-18-00232" ref-type="bibr">34</xref>], thus representing a valid alternative to synthetic drugs in Parkinson&#x02019;s disorder treatment. The neuroprotective effects of NRG-loaded chitosan nanoparticles were demonstrated in vitro in the SH-SY5Y cell line [<xref rid="B35-pharmaceuticals-18-00232" ref-type="bibr">35</xref>]. Within the large panorama of nanocarriers, excellent results in improving the therapeutic performance of natural products were obtained by using lipid- based nanocarriers such as liposomes, microemulsions, solid lipid nanocarriers (SLNs), and nanostructured lipid carriers (NLCs) [<xref rid="B36-pharmaceuticals-18-00232" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00232" ref-type="bibr">37</xref>]. Among them, SLNs represent the most performant carrier as an alternative to traditional colloidal carriers [<xref rid="B38-pharmaceuticals-18-00232" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00232" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00232" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00232" ref-type="bibr">41</xref>]. SLNs are fabricated using a variety of biodegradable lipids and lipidic stabilizers without the use of any organic solvent, are generally recognized as safe (GRAS), and whose sizes, polydispersity, surface charge, short- and long-term stability, drug loading, and release profile can be modulated using a selection of lipids and surfactants. They can be prepared for a wide variety of administration routes, offering several advantages compared to the other nano-scale systems, i.e., the ability to incorporate lipophilic or hydrophilic drugs, targeting options, controlled release, good bioavailability and stability, good tolerability, and a low risk for acute and chronic toxicity [<xref rid="B42-pharmaceuticals-18-00232" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00232" ref-type="bibr">43</xref>].</p><p>Studies are available in the literature describing NRG-SLNs development, although the majority are aimed at the mere physical&#x02013;chemical characterization of the system or an evaluation of the antioxidant, anti-inflammatory, and anticancer efficacy of the nanoformulation. For example, SLNs are able to enhance the cytotoxic effects of NRG against pancreatic cancer cell lines [<xref rid="B44-pharmaceuticals-18-00232" ref-type="bibr">44</xref>] or to improve the neuroprotective effects of NRG in the rotenone-induced Parkinson&#x02019;s disease rodent model, showing the potential to avert the progression of the disease [<xref rid="B45-pharmaceuticals-18-00232" ref-type="bibr">45</xref>]. Pre-treatment of PC12 cell cultures with NRG-SLNs resulted in higher cell survival, increased mitochondrial membrane potential, and reduced autophagic marker expression with respect to free NRG, demonstrating NRG-SLNs formulation as a promising candidate to protect cells from streptozocin-induced neurotoxicity [<xref rid="B34-pharmaceuticals-18-00232" ref-type="bibr">34</xref>]. After intragastric administration in rats, the oral bioavailability of NRG-SLNs was approximately 2.93-fold higher than that of NRG solution, demonstrating SLNs as a safe and effective oral delivery system to enhance the therapeutic potential of NRG in rheumatoid arthritis treatment [<xref rid="B46-pharmaceuticals-18-00232" ref-type="bibr">46</xref>]. A 2.53-fold increase in bioavailability with respect to NRG suspension was also observed as a consequence of the pulmonary administration of NRG-SLNs nanoformulations, showing good potentiality for SLNs as NRG carriers [<xref rid="B47-pharmaceuticals-18-00232" ref-type="bibr">47</xref>].</p><p>To the best of our knowledge, no published papers have evaluated the effectiveness of SLNs formulations in improving the antimicrobial activity of NRG. There is a panoramic lack in the research pertaining to new antibacterial agents; however, due to the interesting antimicrobial properties shown by NRG, this could be largely improved by advancing SLNs nanotechnology. For this reason, in this work we developed NRG-SLNs formulations, and assayed their antibacterial effectiveness in vitro against <italic toggle="yes">Staphylococcus aureus,</italic> including methicillin resistant <italic toggle="yes">S. aureus</italic> (MRSA) as the Gram-positive bacteria, and <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> as the Gram-negative bacteria. Furthermore, the effect on biofilm formation in the <italic toggle="yes">S. aureus</italic> strains was evaluated.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00232"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00232"><title>2.1. Technological Characterization of NRG-SLNs</title><p>The lipophilic nature of NRG prevented its pharmaceutical formulation in liquid and solid dosage forms. Thus, to overcome its solubility issue and obtain a sustained release, we formulated SLNs in which the bioactive molecule was entrapped in the matrix core.</p><p>NRG<sub>x</sub>-SLNs were prepared using different NRG amounts, ranging from 1 to 10%, by means of the solvent emulsification/diffusion method. The diffusion of organic solvents containing lipids and NRG into the aqueous solution facilitated the formation of colloidal suspensions that then underwent ultrasonication to ensure the formation of nanosized systems. COM was used as a lipid phase. This is a mixture of glycerol behenate that presents low cytotoxicity and, due to its amphiphilic properties [<xref rid="B48-pharmaceuticals-18-00232" ref-type="bibr">48</xref>], the ability to efficiently entrap hydrophilic and lipophilic drugs, thus controlling their release [<xref rid="B49-pharmaceuticals-18-00232" ref-type="bibr">49</xref>]. As reported by other authors [<xref rid="B47-pharmaceuticals-18-00232" ref-type="bibr">47</xref>], the amount of lipid and surfactant used in the preparation process influences the physical&#x02013;chemical properties of the SLNs. The lipid and surfactant composition of the NRG-SLNs and the operative conditions were established experimentally in a previous study [<xref rid="B41-pharmaceuticals-18-00232" ref-type="bibr">41</xref>]. The amount of Tween 80 used as a surfactant was chosen based on the sizes of the final formulations. The correct amount permits the generation of SLNs with small sizes; however, an excessive amount could produce foam. Concerning the solvent, we selected ethanol because NRG demonstrates good solubility in this solvent at room temperature, while COM is soluble at temperatures higher than 60 &#x000b0;C. This difference permits separation of the lipid from the NRG, permitting an indirect evaluation of the NRG encapsulated in the SLNs. The COM melts at a temperature higher than 75 &#x000b0;C, thus the emulsification was carried out at 80 &#x000b0;C; the successive cooling down at room temperature permitted the solidification of the lipids into a spherical matrix, coated by Tween 80 and entrapping NRG [<xref rid="B47-pharmaceuticals-18-00232" ref-type="bibr">47</xref>]. On the other hand, the amount of resulting lipid and surfactant is a determinant for establishing the optimal properties of all lipid-based formulations for NRG delivery, such as simple [<xref rid="B50-pharmaceuticals-18-00232" ref-type="bibr">50</xref>] or hybrid nanoemulsions [<xref rid="B51-pharmaceuticals-18-00232" ref-type="bibr">51</xref>].</p><p>The encapsulation parameters for NRG<sub>x</sub>-SLNs are reported in <xref rid="pharmaceuticals-18-00232-t001" ref-type="table">Table 1</xref>. For all the investigated samples, a high E.E. % and D.C. % and a good Yield % were achieved. The formulation prepared with the highest NRG theoretical amount (10%) resulted in the highest performance as far as E.E. % (97.9%, <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) and D.C. % (4.1%, <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) were concerned. The obtained E.E.% demonstrated a very high affinity of NRG for COM and no loss of the drug. Similar results were obtained by Sahu et al. [<xref rid="B52-pharmaceuticals-18-00232" ref-type="bibr">52</xref>] using COM as a lipid, but different surfactants (poloxamer 188 and soya lecithin) and in higher amounts than the Tween 80 present in our nanoformulation. On the other hand, other authors reported lower E.E.% for NRG-SLNs with respect to our nanoparticles, but using glycerylmonooleate as a lipid [<xref rid="B47-pharmaceuticals-18-00232" ref-type="bibr">47</xref>,<xref rid="B53-pharmaceuticals-18-00232" ref-type="bibr">53</xref>], confirming the high affinity of NRG for COM.</p><p>Due to the optimal E.E. % and D.C. % values for the NRG<sub>10</sub>-SLNs formulation, this was chosen in order to proceed with the successive characterizations.</p><sec id="sec2dot1dot1-pharmaceuticals-18-00232"><title>2.1.1. Particle Sizes, Polydispersity Index, and Zeta Potential</title><p><xref rid="pharmaceuticals-18-00232-t002" ref-type="table">Table 2</xref> shows the sizes, polydispersity index (PDI), and zeta potential (&#x003b6;) values of empty SLNs and NRG<sub>10</sub>-SLNs samples, before and after lyophilization. As far as hydrodynamic diameters (D<sub>H</sub>) are concerned, the very small size of SLNs was obtained following an optimized preparation of empty SLNs and NRG<sub>10</sub>-SLNs using a precise quantity of Tween<sup>&#x000ae;</sup> 80 (0.5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), according to the methods reported in previous works [<xref rid="B39-pharmaceuticals-18-00232" ref-type="bibr">39</xref>,<xref rid="B54-pharmaceuticals-18-00232" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-18-00232" ref-type="bibr">55</xref>]. Furthermore, PDI (%) values were determined to be ~0.15, indicating that there were no clusters present and that the population of SLNs was homogeneous in the investigated samples. Finally, both empty SLNs and NRG<sub>10</sub>-SLNs exhibited high negative &#x003b6; values, suggesting that high electrostatic repulsive forces exist between neighboring particles that inhibit aggregation and ensure high physical stability in the systems. No variation in these parameters was observed after lyophilization.</p><p>To confirm the physical stability of NRG<sub>10</sub>-SLNs over time, we maintained the nanoformulation for 30 days in different conditions of light and temperature, then measured the mean sizes, PDI, and &#x003b6; values. No appreciable changes were observed in that time (<xref rid="pharmaceuticals-18-00232-t003" ref-type="table">Table 3</xref>), demonstrating the good physical stability of the system.</p></sec><sec id="sec2dot1dot2-pharmaceuticals-18-00232"><title>2.1.2. In Vitro Drug Release Studies</title><p>NRG release from SLNs was performed using the dialysis method by suspending a weighted amount of NRG<sub>10</sub>-SLNs in a PBS:EtOH mixture (85:15, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) and comparing to a solution of free NRG in the same solvent (<xref rid="pharmaceuticals-18-00232-f001" ref-type="fig">Figure 1</xref>). The quantitative appearance of free NRG was observed in the dialysis medium after approximately 4 h. This trend demonstrated the suitability of the dialysis bag for these studies and allowed us to hypothesize that the release of NRG, when encapsulated in SLNs, is controlled by the SLNs themselves.</p><p>NRG<sub>10</sub>-SLNs exhibited a release profile in which about 25% of the encapsulated NRG was quickly released within the first 5 h of the experiment, followed by a sustained release that saw a cumulative amount of NRG approximating 55% within 24 h, and the remaining 45% of encapsulated NRG slowly released within 10 days. The NRG released in the first 5 h is probably located on or near the surface of the SLNs. The remaining amount is probably uniformly distributed throughout the lipidic matrix and takes a longer time to complete the release. Faster release of NRG was obtained by other authors from SLNs produced using COM or other lipids. For example, SLNs produced with glycerilmonoleate released NRG quantitatively within 60 h, even if the SLNs possess larger sizes (&#x0003e;200 nm) with respect to our nanoformulation [<xref rid="B53-pharmaceuticals-18-00232" ref-type="bibr">53</xref>]. This difference may be due to the excellent affinity of NRG for COM, and the resulting drug&#x02013;lipid association. In order to migrate through the lipid matrix, NRG&#x02013;lipid dissociation must occur, thus contributing to the resulting delay in the diffusion process [<xref rid="B56-pharmaceuticals-18-00232" ref-type="bibr">56</xref>]. On the other hand, it is not only the type of lipid used that determines the release rate of NRG. In fact, Sahu et al. [<xref rid="B52-pharmaceuticals-18-00232" ref-type="bibr">52</xref>], synthesized NRG-SLNs using COM with poloxamer 188 and soya lecithin as the surfactant and co-surfactant. They detected a release of NRG within 24 h, demonstrating that the type of surfactant also plays an important role in drug release in this system.</p><p>Data obtained from the release studies were treated using three different kinetic models, i.e., zero-order, first-order, and the Higuchi model, together with the Korsmayer-Peppas transport model [<xref rid="B57-pharmaceuticals-18-00232" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-18-00232" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-18-00232" ref-type="bibr">59</xref>]. In order to identify the most suitable among the kinetic models, the linear regression coefficients (R<sup>2</sup>) of all models were compared. As evidenced by <xref rid="pharmaceuticals-18-00232-t004" ref-type="table">Table 4</xref>, the highest R<sup>2</sup> value (~1), indicative of a good fit [<xref rid="B57-pharmaceuticals-18-00232" ref-type="bibr">57</xref>], was obtained for the first-order kinetic model.</p><p>According to the literature [<xref rid="B60-pharmaceuticals-18-00232" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceuticals-18-00232" ref-type="bibr">61</xref>] it is well-established that, depending on the type of lipid and the morphology of the SLNs, the release mechanisms involved can be of different types, i.e., diffusion of the drug, swelling, or degradation of the lipid matrix. Specifically, in the case of the NRG<sub>10</sub>-SLNs system and given the lipophilic nature of the matrix, the swelling mechanism is excluded. Furthermore, considering that the in vitro release studies were conducted in the absence of enzymes, lipid degradation can be ruled out. Thus, diffusion represents the unique mechanism underlying NRG release. Based on the Korsmeyer-Peppas model, the value of the transport exponent (n) allows us to recognize the drug release mechanism. The obtained n value ~0.58 indicates a non-Fickian diffusion as the predominant release mechanism for NRG by the NRG<sub>10</sub>-SLNs system [<xref rid="B59-pharmaceuticals-18-00232" ref-type="bibr">59</xref>].</p></sec></sec><sec id="sec2dot2-pharmaceuticals-18-00232"><title>2.2. Chemical&#x02013;Physical Characterization of NRG<sub>10</sub>-SLNs</title><p>TGA analyses were performed in an inert environment at a heating rate of 10 &#x000b0;C/min. For each sample, the TGA analysis was evaluated up to 700 &#x000b0;C to investigate the thermal stability of free NRG and NRG<sub>10</sub>-SLNs. <xref rid="pharmaceuticals-18-00232-f002" ref-type="fig">Figure 2</xref>a shows the TGA profiles of COM, free NRG, empty SLNs, the NRG<sub>10</sub>-SLNs system, and an NRG + empty SLNs physical mixture. Firstly, the ~7% weight loss observed for empty SLNs, the NRG<sub>10</sub>-SLNs nanoformulation, and the physical mixture in the temperature range 55&#x02013;110 &#x000b0;C, is due to the loss of water absorbed during the preparation process. On the other hand, the same thermal event is absent from the profile of COM, which shows a 2% loss of weight at higher temperatures (from 120 &#x000b0;C to 250 &#x000b0;C). For all samples, we observed the onset of degradation at a temperature up to 280 &#x000b0;C. Particularly, from derivative of the TG curve (<xref rid="app1-pharmaceuticals-18-00232" ref-type="app">Figure S2 in Supplementary Materials</xref>) we can observe the degradation of free NRG at 335 &#x000b0;C, corresponding to the maximum slope on the TG curve (see red line in <xref rid="pharmaceuticals-18-00232-f002" ref-type="fig">Figure 2</xref>a). The NRG<sub>10</sub>-SLNs pyrolysis curves showed an increased stability in NRG as a consequence of its encapsulation, evidenced by the derivative of the TG curve (see black line in <xref rid="app1-pharmaceuticals-18-00232" ref-type="app">Figure S2</xref>) as an intense signal of degradation at about 425 &#x000b0;C, almost overlapping with the degradation of empty SLNs. The presence of a weak signal on the NRG<sub>10</sub>-SLNs derivative curve at about 280 &#x000b0;C could reflect the degradation of the low amount of free NRG present on the surface of the SLNs nanoformulation. The physical mixture, on the other hand, undergoes gradual degradation starting at a lower temperature with respect to the nanoformulation (see green line in <xref rid="app1-pharmaceuticals-18-00232" ref-type="app">Figure S2</xref>), probably reflecting the presence of NRG as a non-encapsulated molecule.</p><p>The freeze-dried NRG<sub>10</sub>-SLNs sample was subjected to a calorimetric analysis to determine the state of the incorporated molecules. In <xref rid="pharmaceuticals-18-00232-f002" ref-type="fig">Figure 2</xref>b, DSC curves of COM, free NRG, empty SLNs, the physical mixture of empty SLNs and NRG, and the NRG<sub>10</sub>-SLNs formulation are shown. Due to the chemical composition of COM (it is composed of non-pure triacylglycerols), its DSC curve shows two endothermic peaks, the main one at around 75 &#x000b0;C, probably due to metastable polymorphic forms [<xref rid="B48-pharmaceuticals-18-00232" ref-type="bibr">48</xref>], and the second one at approximately 136 &#x000b0;C. A shift towards higher temperatures was observed for the first peak, and the disappearance of the peak at 136 &#x000b0;C could be as a consequence of the thermal stress suffered by the lipid during SLNs preparation (see empty SLNs). NRG shows an endothermic melting peak at 250 &#x000b0;C, indicative of the crystalline state of the molecule. The physical mixture exhibits two endothermic peaks: one at 240 &#x000b0;C due to the presence of free NRG and the other at about 90 &#x000b0;C corresponding to the SLNs. However, in the DSC curve of the NRG<sub>10</sub>-SLNs, the endothermic peak for the drug disappeared, revealing that NRG interacts with the lipid, via hydrogen bonds or van Deer Waals interactions, and is mostly located inside the SLNs.</p><p>The X-ray diffraction study was employed to ascertain the state of NRG after encapsulation in the system. The XRD spectra of COM, free NRG, empty SLNs, the physical mixture of empty SLNs and NRG, and NRG<sub>10</sub>-SLNs are shown in <xref rid="pharmaceuticals-18-00232-f002" ref-type="fig">Figure 2</xref>c. Free NRG and the physical mixture present crystalline properties with very sharp peaks in the 2 theta range from 3&#x000b0; to 40&#x000b0;, while COM showed a single diffraction peak at 2 theta ~21.0&#x000b0;. Sharp peaks were observed in the diffractograms of the empty SLNs, demonstrating a different crystal structure for the lipids in the matrix compared to the bulk solid lipids. The XRD spectra of the physical mixture show clear peaks of NRG (indicated by black rectangles), evidencing the presence of NRG in a crystalline state. However, the disappearance of the main free NRG peaks in the diffractograms for the NRG<sub>10</sub>-SLNs could be due to the incorporation of NRG into the lipid crystal lattice [<xref rid="B41-pharmaceuticals-18-00232" ref-type="bibr">41</xref>] and the creation of non-covalent NRG-SLNs interactions. This drug&#x02013;lipid association could be responsible for the sustained release of NRG previously observed. Dissociation of this complex is needed to permit the migration of NRG through the lipid matrix, producing as a consequence a retardation in the diffusion process [<xref rid="B56-pharmaceuticals-18-00232" ref-type="bibr">56</xref>].</p><p><xref rid="pharmaceuticals-18-00232-f003" ref-type="fig">Figure 3</xref> shows the structure (panel a) and the experimental &#x000b5;-Raman spectrum of NRG (panel b and c). The latter, although characterized by an extremely composite profile, shows a series of main bands that extend within a wavenumber range from ~500 cm<sup>&#x02212;1</sup> to ~1800 cm<sup>&#x02212;</sup><sup>1</sup>. The peak at ~555 cm<sup>&#x02212;</sup><sup>1</sup> may be associated with OCC bending of the R<sub>a</sub> and R<sub>b</sub> rings. The peak at ~712 cm<sup>&#x02212;</sup><sup>1</sup> can be associated with the O=CCC out-of-plane bending mode, while the contribution centered at ~890 cm<sup>&#x02212;</sup><sup>1</sup> is due to the CCO bending modes, both attributable to the R<sub>b</sub> ring. Again, the pair of contributions at ~1014 cm<sup>&#x02212;</sup><sup>1</sup> and ~1066 cm<sup>&#x02212;</sup><sup>1</sup>, clearly visible within the investigated range, can be attributed, respectively, to HCCC torsions involving the R<sub>c</sub> ring and to the CO stretching modes of the R<sub>a</sub> ring, while the contribution at ~1316 cm<sup>&#x02212;</sup><sup>1</sup> is attributable to the C-OH (C<sub>5</sub>&#x02013;OH) deformation modes of the R<sub>b</sub> ring. Within the 1500&#x02013;1700 cm<sup>&#x02212;</sup><sup>1</sup> spectral range, it is possible to observe a broadband constituted by the envelope of two distinct vibrational contributions, centered at ~1590 cm<sup>&#x02212;</sup><sup>1</sup> and ~1622 cm<sup>&#x02212;</sup><sup>1</sup>, and attributable, respectively, to the CC stretching of the R<sub>a</sub>, R<sub>b,</sub> and R<sub>c</sub> rings and to the CO (C<sub>10</sub>=O<sub>17</sub>) stretching modes of the R<sub>b</sub> ring [<xref rid="B62-pharmaceuticals-18-00232" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceuticals-18-00232" ref-type="bibr">63</xref>]. Finally, contributions deriving from the CH stretching modes associated with the R<sub>a</sub> and R<sub>c</sub> rings are also present in the wavenumber range from ~2900 cm<sup>&#x02212;1</sup> to ~3100 cm<sup>&#x02212;1</sup>. <xref rid="pharmaceuticals-18-00232-f003" ref-type="fig">Figure 3</xref>c shows the experimental &#x000b5;-Raman spectra, collected in the 1500&#x02013;1700 cm<sup>&#x02212;1</sup> wavenumber range, respectively associated with NRG and the NRG<sub>10</sub>-SLNs system. The focusing of attention on this spectral region is mainly due to the latter being free of vibrational contributions from the solid&#x02013;lipid matrix (see inset of <xref rid="pharmaceuticals-18-00232-f003" ref-type="fig">Figure 3</xref>c), thus allowing us to directly observe variations in the vibrational bands of the NRG as a consequence of the drug entrapment within the investigated matrix.</p><p>From the comparison between the &#x000b5;-Raman spectra associated with NRG and NRG<sub>10</sub>-SLNs, we observe a clear reduction in the intensity of the vibrational modes centered at ~1590 cm<sup>&#x02212;</sup><sup>1</sup> and ~1622 cm<sup>&#x02212;</sup><sup>1</sup> and attributable, as previously described, to the CC stretching modes of the R<sub>a</sub>, R<sub>b</sub>, and R<sub>c</sub> rings (~1590 cm<sup>&#x02212;</sup><sup>1</sup>), and to the CO (C<sub>10</sub>=O<sub>17</sub>) stretching modes of the R<sub>b</sub> ring (~1622 cm<sup>&#x02212;</sup><sup>1</sup>) of NRG. This reduction, as already justified in previous reports on similar systems [<xref rid="B30-pharmaceuticals-18-00232" ref-type="bibr">30</xref>], suggests a <italic toggle="yes">hindering</italic> of the functional groups responsible for the aforementioned vibrations, as a consequence of the activation of <italic toggle="yes">&#x0201c;host&#x02013;guest&#x0201d;</italic> interactions that drive the encapsulation of the drug in the studied SLNs.</p><p>Morphological characterization of lyophilized NRG<sub>10</sub>-SLNs was carried out, before and after redispersion, by scanning transmission electron microscopy (STEM) (<xref rid="pharmaceuticals-18-00232-f004" ref-type="fig">Figure 4</xref>). The solid sample appears as an aggregate powder, probably due to the presence of trehalose, used as a cryoprotectant, that wraps around the nanoparticles and keeps them close to each other (<xref rid="pharmaceuticals-18-00232-f004" ref-type="fig">Figure 4</xref>a). The redispersed powder showed spherical nanoparticles with a smooth surface and a very low degree of aggregation (<xref rid="pharmaceuticals-18-00232-f004" ref-type="fig">Figure 4</xref>b).</p></sec><sec id="sec2dot3-pharmaceuticals-18-00232"><title>2.3. Antibacterial Activity</title><p>The results of the antibacterial tests are shown in <xref rid="pharmaceuticals-18-00232-t005" ref-type="table">Table 5</xref>. NRG possesses bacteriostatic activity rather than bactericidal effects, showing an MIC value of 0.5 mg/mL against <italic toggle="yes">S. aureus</italic> ATCC 6538 and <italic toggle="yes">S. aureus</italic> (MRSA) ATCC 43300 and 1 mg/mL against <italic toggle="yes">E. coli.</italic> No activity was evident against <italic toggle="yes">P. aeruginosa</italic> at the highest concentration assayed. Similar results were obtained by Wang et al. [<xref rid="B9-pharmaceuticals-18-00232" ref-type="bibr">9</xref>] against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">E. coli</italic>, evidencing that the latter was less susceptible to NRG treatment. The cell wall structure in Gram-positive and Gram-negative bacteria and the mechanism of action of NRG may be responsible for the difference in activity [<xref rid="B64-pharmaceuticals-18-00232" ref-type="bibr">64</xref>]. Gram-negative bacteria possess a complex outer membrane that is less permeable and provides an additional selective barrier that can effectively hinder the access of hydrophobic compounds such as NRG to the cytoplasmic membrane [<xref rid="B9-pharmaceuticals-18-00232" ref-type="bibr">9</xref>].</p><p>Regarding the nanoformulation, empty SLNs showed antibacterial activity with MIC values of 1 and 0.5 mg/mL toward <italic toggle="yes">S. aureus</italic> ATCC 6538 and <italic toggle="yes">S. aureus</italic> (MRSA) ATCC 43300, respectively. On the contrary, no activity was reported against either Gram-negative bacteria (<italic toggle="yes">E. coli</italic> and <italic toggle="yes">P. aeruginosa</italic>) at the highest concentration assayed. It is conceivable to suppose that the surfactant (Tween 80<sup>&#x000ae;</sup>) used for the nanoparticles preparation and adsorbed on their surface could be responsible for the antibacterial effect. Indeed, Tween 80 is known to interact with the bacterial surface, enhancing cell permeability and membrane fluidity [<xref rid="B65-pharmaceuticals-18-00232" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-18-00232" ref-type="bibr">66</xref>]. Specifically, Tween 80 at concentrations of 0.25% and 0.5% has been reported to reduce the viability of planktonic <italic toggle="yes">S. aureus</italic> cells and the biofilm formation capacity [<xref rid="B67-pharmaceuticals-18-00232" ref-type="bibr">67</xref>]. Furthermore, Maurya et al. [<xref rid="B65-pharmaceuticals-18-00232" ref-type="bibr">65</xref>], demonstrated that Tween 80 adsorbed onto SLNs efficiently disrupts <italic toggle="yes">S. aureus</italic> biofilms.</p><p>NRG<sub>10</sub>-SLNs showed, in terms of MIC values, similar (against <italic toggle="yes">S. aureus</italic> ATCC 6538) or higher (against <italic toggle="yes">S. aureus</italic> ATCC 43300) antibacterial activity, with respect to free NRG, and always higher with respect to empty SLNs (see <xref rid="pharmaceuticals-18-00232-t005" ref-type="table">Table 5</xref>). It can be assumed that the permeabilizing activity exerted on the cell membrane by Tween 80, which coats the SLNs, facilitates the entry of NRG released by the nanoformulation into the bacterial cell, where it directly targets nucleic acids, thus enhancing its action. Furthermore, some considerations need to be made taking into account the release profile of NRG from SLNs. </p><p>The nanoformulation progressively releases NRG (see <xref rid="pharmaceuticals-18-00232-f001" ref-type="fig">Figure 1</xref>), reaching a cumulative amount of 55% in 24 h, i.e., an amount of NRG available to interact with the bacteria equal to about half of the dose of NRG when free in the medium. Despite this, the antibacterial activity of the NRG loaded-SLNs was similar or improved with respect to NRG alone, highlighting the role of the nanocarrier in strengthening the activity of the molecule. In addition, the NRG<sub>10</sub>-SLNs inhibited bacterial metabolic activity more effectively, resulting in a lower presence of viable cells up to 0.06 mg/mL, compared to free NRG (<xref rid="pharmaceuticals-18-00232-f005" ref-type="fig">Figure 5</xref>). This is probably due to the progressive release of NRG from the SLNs allowing its continuous availability and distribution to the bacterial cells. These observations suggest that, for a combination of different reasons, SLNs are effective carriers for NRG.</p><p>Based on the antibacterial activity observed against the two <italic toggle="yes">S. aureus</italic> strains, we evaluated the influence of sub-MIC concentrations of NRG<sub>10</sub>-SLNs, free NRG, and empty SLNs on biofilm formation (<xref rid="pharmaceuticals-18-00232-f006" ref-type="fig">Figure 6</xref>). The results show the highest inhibition of biofilm production for NRG<sub>10</sub>-SLNs with respect to the free NRG. Notably, a biofilm reduction of 42% and 53% with respect to the free NRG (reduction of 35% and 38%) for <italic toggle="yes">S. aureus</italic> ATCC 6538 and <italic toggle="yes">S. aureus</italic> ATCC 43300 MRSA, respectively, was detected.</p><p>The activity of NRG on microbial biofilm is acknowledged in the literature. In this regard, Wen et al. [<xref rid="B68-pharmaceuticals-18-00232" ref-type="bibr">68</xref>] reported the inhibiting effect of NRG on <italic toggle="yes">S. aureus</italic> adhesion to solid surfaces and the subsequent formation of biofilm, due to a reduction in bacterial surface hydrophobicity and esopolysaccharide production. Furthermore, it is also known that interference with biofilm formation may be due to the physical action of the surfactant on the substrate surface [<xref rid="B69-pharmaceuticals-18-00232" ref-type="bibr">69</xref>]. These observations could explain the improvement in the antibiofilm activity of NRG<sub>10</sub>-SLNs with respect to the free NRG.</p></sec></sec><sec id="sec3-pharmaceuticals-18-00232"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00232"><title>3.1. Materials</title><p>Naringenin (MW 272.26, NRG &#x02265; 95%) was purchased from Aldrich Chemical Company, Inc (Milwaukee, WI, USA); Compritol<sup>&#x000ae;</sup> 888 ATO (COM) was kindly supplied by Gattefoss&#x000e9; SAS (Lyon, France); Tween<sup>&#x000ae;</sup> 80 and trehalose from Saccharomyces Cerevisiae &#x02265; 99% were purchased from Sigma Aldrich (St. Louis, MO, USA). Ethanol (EtOH) HPLC grade is a Merck<sup>&#x000ae;</sup> (Darmstadt, Germany) product. Double-distilled water filtered through 0.22 &#x000b5;m Millipore<sup>&#x000ae;</sup> GSWP filters (Bedford, MA, USA) was used throughout the study. All other products and reagents were of analytical grade. Dialysis bags were Spectra/Por<sup>&#x000ae;</sup> 18 &#x000d7; 11.5 mm Dialyse-Membrane (MWCO: 1000, Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA).</p></sec><sec id="sec3dot2-pharmaceuticals-18-00232"><title>3.2. Preparation of Empty SLNs and NRG-SLNs</title><p>Empty SLNs were prepared using the method reported by Butani et al. [<xref rid="B70-pharmaceuticals-18-00232" ref-type="bibr">70</xref>], with slight modifications. Briefly, 50 mg of COM was solubilized in 2.5 mL of EtOH to form the lipid phase, whereas the aqueous phase was prepared by adding Tween<sup>&#x000ae;</sup> 80 (0.5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) to 11.25 mL of double-distilled water [<xref rid="B71-pharmaceuticals-18-00232" ref-type="bibr">71</xref>]. Initially, the two phases were heated at a temperature above 80 &#x000b0;C to ensure the complete melting of the lipid and total dissolution of the surfactant. The Ultra-Turrax T 25 (IKA-Werke, Staufen, Germany) was used during the addition of the lipid phase into the aqueous phase (within 7 min) to ensure high-speed homogenization (11,000 rpm). In order to obtain a particle size as small as possible, the resulting colloidal dispersions were immersed in an ultrasound bath (Bandelin Sonorex<sup>&#x000ae;</sup> RK 514, amplitude delivered ranges between 3 and 5 &#x000b5;m, Berlin, Germany) for 5 min. After that, the colloidal dispersions were allowed to cool down to room temperature by placing them on a magnetic stirrer (500 rpm) for 24 h to ensure complete removal of the organic solvent. The obtained sample underwent centrifugation at 5000 rpm for 20 min (Heraeus Megafuge 16, ThermoFisher Scientific, Waltham, MA, USA) to remove the COM that did not interact. The pellet was removed and the supernatant containing the SLNs was collected, trehalose (5%, <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) was added as a cryoprotectant, and the solution was lyophilized (&#x02212;53 &#x000b0;C, 43 mTorr) for 72 h (BenchTop K Series Freeze Dryers, VirTis Gardiner, Gardiner, NY, USA).</p><p>The SLNs loaded with NRG (NRG-SLNs) were prepared using the same procedure described above, by solubilizing NRG in the heated ethanolic solution of COM at different concentrations, from 1 to 10% (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>), based on the weight of lipid (namely, NRG<sub>x</sub>-SLNs, with x = 1, &#x02026; 10). After centrifugation of the obtained colloidal suspension at 5000 rpm, the supernatant containing NRG<sub>x</sub>-SLNs was added to trehalose (5%, <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) and lyophilized for 72 h. The pellet, containing the non-encapsulated NRG and the non-interacting lipid, was used for the indirect determination of encapsulated NRG. Specifically, the pellet was added to cold EtOH (5 mL) and magnetically stirred at room temperature for 5 min to solubilize the NRG. The non-interacting COM remained in suspension since it is insoluble in ethanol at temperatures below 60 &#x000b0;C. Thus, the suspension was filtered through 0.22 &#x000b5;m PTFE filters (Millipore<sup>&#x000ae;</sup>), and the NRG in the filtrate was quantified by UV&#x02013;Vis spectroscopy as described in <xref rid="sec3dot5-pharmaceuticals-18-00232" ref-type="sec">Section 3.5</xref> [<xref rid="B72-pharmaceuticals-18-00232" ref-type="bibr">72</xref>]. To ensure the full recovery of NRG, this process was repeated until no bioactive molecule was detected. The encapsulated NRG was determined as the difference between the total amount of NRG added during the preparation of SLNs and the non-encapsulated NRG present in the pellet. The experiment was performed in triplicate and the results were expressed as mean &#x000b1; standard deviation (S.D.).</p></sec><sec id="sec3dot3-pharmaceuticals-18-00232"><title>3.3. Technological Characterization of NRG-SLNs</title><p>To determine the yield percentage (Yield %), the lyophilized empty SLNs and the NRG<sub>x</sub>-SLNs were weighed, and the following formula (Equation (1)) was used:<disp-formula id="FD1-pharmaceuticals-18-00232"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Y</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">%</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The entrapment efficiency percentage (E.E. %) and the drug content percentage (D.C. %) were determined using the following equations (Equations (2) and (3)):<disp-formula id="FD2-pharmaceuticals-18-00232"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">%</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD3-pharmaceuticals-18-00232"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">%</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>&#x000a0;</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Mean particle sizes, polydispersity index (PDI), and zeta potential (&#x003b6;) of empty SLNs and NRG<sub>10</sub>-SLNs were measured before and after lyophilization using a Zeta sizer 3000 instrument (Malvern Panalytical Ltd., Malvern, UK) with a Dynamic Light Scattering (DLS) technique. Before the analysis, the samples were diluted 100 times using water stored at a specific temperature to prevent multiple scattering effects. The measurements were repeated three times for accuracy.</p></sec><sec id="sec3dot4-pharmaceuticals-18-00232"><title>3.4. In Vitro Drug Release Studies</title><p>The lyophilized NRG<sub>10</sub>-SLNs containing 1 mg of NRG were suspended in 5 mL of phosphate buffer solution (PBS, pH 7.4). The suspension was transferred into a pre-activated dialysis bag and then placed in a beaker containing 150 mL of PBS:EtOH mixture (85:15, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). EtOH was added to avoid the precipitation of NRG (water solubility of ~4.38 &#x003bc;g/mL) [<xref rid="B73-pharmaceuticals-18-00232" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceuticals-18-00232" ref-type="bibr">74</xref>]. Throughout the experiment, the dialysis medium was constantly agitated with a magnetic stirrer at 300 rpm and maintained at 37.0 &#x000b1; 0.5 &#x000b0;C (Telesystem 15.40 thermostat bath with Telemodul 40 C control unit). To ensure sink conditions, the medium was periodically replaced with a preheated (37 &#x000b0;C) fresh mixture of PBS:EtOH (85:15, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). All collected volumes were evaporated under vacuum at 25.0 &#x000b1; 0.1 &#x000b0;C, and the resulting residues were dissolved in 2 mL of EtOH. The samples were then analyzed by UV&#x02013;Vis spectroscopy [<xref rid="B72-pharmaceuticals-18-00232" ref-type="bibr">72</xref>], as described in <xref rid="sec3dot5-pharmaceuticals-18-00232" ref-type="sec">Section 3.5</xref>.</p><p>Free NRG (1 mg), corresponding to the same amount contained in the NRG<sub>10</sub>-SLNs, was solubilized in a PBS&#x02013;EtOH mixture (85:15, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) and subjected to dialysis to verify the suitability of the chosen bag. The same procedure performed for NRG<sub>10</sub>-SLNs was followed and NRG was determined by UV&#x02013;Vis spectroscopy (see <xref rid="sec3dot5-pharmaceuticals-18-00232" ref-type="sec">Section 3.5</xref>).</p><p>All experiments were performed in triplicate and data were expressed as the mean value &#x000b1; S.D. The acquired data for NRG<sub>10</sub>-SLNs were analyzed using the Korsmayer-Peppas transport model in conjunction with three distinct kinetic models, namely the zero-order, first-order, and Higuchi models [<xref rid="B57-pharmaceuticals-18-00232" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-18-00232" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-18-00232" ref-type="bibr">59</xref>].</p></sec><sec id="sec3dot5-pharmaceuticals-18-00232"><title>3.5. UV&#x02013;Vis Apparatus and Method Validation</title><p>The quantitative analysis of NRG was carried out by UV&#x02013;Vis spectroscopy (FullTech Instruments, Rome, mod. PG T80), using 10.00 mm quartz cells (Hellma Italia S.r.l., Milano, Italia). The samples were opportunely diluted with ethanol and analyzed at &#x003bb;<sub>max</sub> of 289 nm.</p><p>The UV&#x02013;Vis method was validated for linearity, sensitivity, and repeatability [<xref rid="B72-pharmaceuticals-18-00232" ref-type="bibr">72</xref>]. We prepared a stock solution of NRG in ethanol by solubilizing 10 mg in 50 mL of the solvent in a calibrated flask, obtaining a solution containing 200 &#x003bc;g/mL of NRG. Then, 5 mL of the stock solution was placed into a calibrated flask and diluted with 50 mL ethanol, obtaining 20 &#x003bc;g/mL NRG. This solution was scanned in the range of 200&#x02013;600 nm to determine the maximum absorption.</p><p>A calibration curve was constructed in the concentration range of 28&#x02013;0.93 &#x003bc;g/mL, starting from the stock solution, obtaining an R<sup>2</sup> equal to 0.9952. Each concentration was prepared in six replicates and analyzed in triplicate. The precision of the analytical method was determined intra-day and inter-day by analyzing three of the calibration standards (28, 10, and 1 &#x003bc;g/mL) three times during the same day and the next three days. Limit of detection (LOD) and limit of quantitation (LOQ) were determined based on the Equations (4) and (5):<disp-formula>LOD = 3.3 &#x003c3;/S = 0.017 &#x003bc;g/mL<label>(4)</label></disp-formula><disp-formula>LOQ = 10 &#x003c3;/S = 0.52 &#x003bc;g/mL<label>(5)</label></disp-formula>
where &#x003c3; is the standard deviation of the intercept, and S is the slope of the calibration curve.</p></sec><sec id="sec3dot6-pharmaceuticals-18-00232"><title>3.6. Physical Stability of NRG<sub>10</sub>-SLNs Formulation</title><p>The physical stability of the optimized NRG<sub>10</sub>-SLNs formulation was evaluated over time in different conditions of temperature and light. Briefly, the NRG<sub>10</sub>-SLNs suspension was maintained at 4&#x000b0; C or 25 &#x000b0;C in the dark and in daylight for 30 days. At timed intervals (1, 7, 15, and 30 days), the suspension was analyzed for mean particle sizes, PDI, and &#x003b6;.</p></sec><sec id="sec3dot7-pharmaceuticals-18-00232"><title>3.7. Physical&#x02013;Chemical Characterization of NRG<sub>10</sub>-SLNs</title><p>The TAQ500 equipment (TA Instruments, New Castle, DE, USA) was used to carry out thermogravimetric analysis (TGA) and differential scanning calorimetry analysis (DSC). TGA scans were performed using a 100 mL/min argon flow. Following a vacuum drying process, all samples were heated to 700 &#x000b0;C at a rate of 10 &#x000b0;C/min. DSC analysis was carried out at room temperature up to 350 &#x000b0;C at a heating rate of 5 &#x000b0;C/min, while nitrogen flow was 50 mL/min.</p><p>X-ray diffraction (XRD) experiments were run at room temperature using a Bragg&#x02013;Brentano theta&#x02013;2theta setup with Cu K<sub>&#x003b1;</sub> radiation (40 V, 40 mA) on a Bruker D8 Advance diffractometer (Bruker, Karlsruhe, Germany). At a step of 0.2&#x000b0;/s, XRD patterns were obtained in the 5&#x02013;80&#x000b0; range. A comparison was made between the diffraction peaks and the JCPDS (Joint Committee on Powdered Diffraction Standards) database.</p><p>The &#x000b5;-Raman measurements were carried out on both NRG and NRG-SLNs systems, in the solid state using a portable spectrometer &#x0201c;BTR 111 Mini-RamTM&#x0201d; (B&#x00026;W Tek, Inc., Newark, NJ, USA). This instrument operates with an excitation wavelength of 785 nm (laser diode), a maximum laser power of 280 mW, and a thermoelectrically cooled CCD detector. The laser output power has been appropriately adjusted to guarantee the best signal/noise ratio while maintaining low integration times. The &#x000b5;-Raman spectra were acquired in the 65&#x02013;3150 cm<sup>&#x02212;1</sup> range with a resolution of 10 cm<sup>&#x02212;1</sup> and an acquisition time of 10 s &#x000d7; 32 scans. To guarantee the best possible performance, a preliminary calibration procedure was carried out on the instrument, exploiting the peak at 520.6 cm<sup>&#x02212;1</sup> of a silicon chip. The spectrometer used is also equipped with a BAC151B Raman microscope on which an 80&#x000d7; objective was mounted, allowing microscopy measurements with a working distance of 1.25 mm and a laser spot size on the sample surface of ~25 &#x000b5;m. For our measurements, the maximum power delivered to the system was ~120 mW.</p><p>A Jeol JEM 2010F (JEOL, Ltd., Tokyo, Japan) transmission electron microscope (TEM) was used for the morphological characterization of lyophilized NRG<sub>10</sub>-SLNs, before and after redispersion. The experiments were performed at 200 kV of accelerating voltage.</p></sec><sec id="sec3dot8-pharmaceuticals-18-00232"><title>3.8. Antibacterial Activity</title><p>The antibacterial activity experiments were performed with American Type Culture Collection (ATCC) reference strains. Specifically, <italic toggle="yes">Staphylococcus aureus</italic> ATCC 6538, methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) ATCC 43300, <italic toggle="yes">Escherichia coli</italic> ATCC 10536, and <italic toggle="yes">Pseudomonas aeruginosa</italic> ATCC 9027 were used as the representative Gram positive and Gram negative bacteria. The strains were stored at 70 &#x000b0;C in Microbanks&#x02122; (Pro-Lab Diagnostics, Neston, UK). Cultures were grown in Mueller&#x02013;Hinton Broth (MHB, Oxoid) for 24 h before subjecting them to the assay.</p><p>The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of free NRG, NRG<sub>10</sub>-SLNs, and empty SLNs were determined according to the guidelines issued by the Clinical and Laboratory Standards Institute, CLSI (2018) [<xref rid="B75-pharmaceuticals-18-00232" ref-type="bibr">75</xref>] with some modifications. The samples were diluted twofold in 96-well round-bottomed plates using MHB. Free NRG was assayed after solubilization in dimethylsulfoxide (DMSO). Overnight bacterial cultures were inoculated to yield a final concentration of 5 &#x000d7; 10<sup>5</sup> CFU/mL, confirmed by viable counts. The MIC was considered as the lowest concentration of each sample to induce a complete inhibition of visible bacterial growth after incubation for 24 h. To evaluate the inhibition of metabolic bacterial activity, 20 &#x003bc;L of 2,3,5-triphenyl tetrazolium chloride (TTC) 0.125% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) was added to all the wells, followed by 1 h of incubation. The tetrazolium salt is frequently employed in MIC determinations; when dissolved in water it is colorless, but it turns red when metabolically active bacteria are present. This red color is directly correlated with the number of living cells.</p><p>The MBC was determined by seeding 20 &#x000b5;L from all clear-colored MIC wells onto agar plates and was defined as the lowest concentration of compound that killed 99.9% of the inoculum. MHB and MHB with 1% DMSO were used as growth controls. As a positive drug reference standard, ofloxacin was employed. Modal results were computed by evaluating the data from a minimum of three replicates.</p></sec><sec id="sec3dot9-pharmaceuticals-18-00232"><title>3.9. Effect on Biofilm Formation</title><p>The effect of NRG<sub>10</sub>-SLNs, free NRG, and empty SLNs on the biofilm-forming ability of <italic toggle="yes">S. aureus</italic> ATCC 6538 and <italic toggle="yes">S. aureus</italic> ATCC 43300 (MRSA) was tested on polystyrene flat-bottomed microtitre plates as previously described [<xref rid="B76-pharmaceuticals-18-00232" ref-type="bibr">76</xref>]. Overnight cultures in TSB + 1% glucose (TSBG) of <italic toggle="yes">S. aureus</italic> strains were adjusted in TSBG to 1 &#x000d7; 10<sup>6</sup> CFU/mL and were dispensed into each well of 96-well polystyrene flat-bottomed microtitre plates containing twofold dilutions of the NRG<sub>10</sub>-SLNs, free NRG, and empty SLNs ranging from 0.5 &#x000d7; MIC to 0.125 x MIC. After incubation at 37 &#x000b0;C for 24 h, the planktonic phase was removed and each well was washed twice with sterile PBS (pH 7.4), dried, stained with 0.1% safranin, and washed with water. The stained biofilm biomass was resuspended in 30% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) acetic acid and OD<sub>492</sub> was measured using a spectrophotometer EIA reader. A biofilm control consisting of a TSBG medium was included. The reduction percentage of biofilm biomass was calculated using the following equation (Equation (6)):<disp-formula>100 &#x02212; (mean OD<sub>492</sub> of sample well/mean OD<sub>492</sub> of control well) &#x000d7; 100<label>(6)</label></disp-formula></p></sec><sec id="sec3dot10-pharmaceuticals-18-00232"><title>3.10. Statistical Analysis</title><p>Each value is expressed as mean &#x000b1; S.D., and three separate tests were conducted for every analysis. A two-way analysis of variance (ANOVA) was used to analyze the data, and for multiple comparisons, a Bonferroni post hoc test was used [<xref rid="B77-pharmaceuticals-18-00232" ref-type="bibr">77</xref>]. A significant value was defined as <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00232"><title>4. Conclusions</title><p>In this work, SLNs were formulated to obtain a sustained release of NRG and an improvement in its antibacterial and antibiofilm effectiveness. NRG-SLNs formulations were prepared using solvent emulsification/diffusion and ultrasonication methods, selecting Compritol<sup>&#x000ae;</sup> 888 ATO (COM) as the lipid and Tween 80 as the surfactant. The optimized NRG<sub>10</sub>-SLNs system exhibited excellent nanometer sizes (approximately 50 nm) and encapsulation efficiency (97.9%), due to the high affinity of NRG with the lipid used for the SLNs synthesis. TGA, DSC, XRD, and &#x000b5;-Raman techniques confirm this strong interaction, responsible for the prolonged drug release in vitro. Finally, antibacterial activity studies were performed in vitro on Gram-positive and Gram-negative bacteria. An improvement in antibacterial activity for the NRG-loaded SLNs was observed against <italic toggle="yes">S. aureus</italic> strains, probably due to the interaction between the surfactant coating the SLNs and the bacterial surface. A similar trend was observed for the biofilm inhibition.</p><p>Our study demonstrates the efficacy of NRG<sub>10</sub>-SLNs as an innovative antibacterial system towards <italic toggle="yes">S. aureus</italic> strains, providing a basis for the development of a liquid form pharmaceutical dosage for the treatment of topical ocular infections. Ex vivo studies on excited rabbit cornea are in progress to confirm the potentiality of our system.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00232"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020232/s1">https://www.mdpi.com/article/10.3390/ph18020232/s1</uri>, Figure S1: Chemical structure of naringenin; Figure S2: Derivative thermogravimetric analysis.</p><supplementary-material id="pharmaceuticals-18-00232-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00232-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, F.D.G. and R.S.; methodology, R.S., S.T. and C.A.V.; investigation, F.D.G., F.C., N.T., C.C., G.G. and S.T.; data curation, F.D.G., N.T. and C.A.V.; writing&#x02014;original draft preparation, F.D.G. and A.N.; writing&#x02014;review and editing, F.D.G., V.V., A.N., C.A.V. and R.S.; validation, F.D.G. and C.A.V. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>We have no other data to share.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00232"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guedes</surname><given-names>B.N.</given-names></name>
<name><surname>Krambeck</surname><given-names>K.</given-names></name>
<name><surname>Durazzo</surname><given-names>A.</given-names></name>
<name><surname>Lucarini</surname><given-names>M.</given-names></name>
<name><surname>Santini</surname><given-names>A.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.B.P.P.</given-names></name>
<name><surname>Fathi</surname><given-names>F.</given-names></name>
<name><surname>Souto</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Natural Antibiotics against Antimicrobial Resistance: Sources and Bioinspired Delivery Systems</article-title><source>Braz. J. Microbiol.</source><year>2024</year><volume>55</volume><fpage>2753</fpage><lpage>2766</lpage><pub-id pub-id-type="doi">10.1007/s42770-024-01410-1</pub-id><pub-id pub-id-type="pmid">38888693</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00232"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shamsudin</surname><given-names>N.F.</given-names></name>
<name><surname>Ahmed</surname><given-names>Q.U.</given-names></name>
<name><surname>Mahmood</surname><given-names>S.</given-names></name>
<name><surname>Ali Shah</surname><given-names>S.A.</given-names></name>
<name><surname>Khatib</surname><given-names>A.</given-names></name>
<name><surname>Mukhtar</surname><given-names>S.</given-names></name>
<name><surname>Alsharif</surname><given-names>M.A.</given-names></name>
<name><surname>Parveen</surname><given-names>H.</given-names></name>
<name><surname>Zakaria</surname><given-names>Z.A.</given-names></name>
</person-group><article-title>Antibacterial Effects of Flavonoids and Their Structure-Activity Relationship Study: A Comparative Interpretation</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1149</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27041149</pub-id><pub-id pub-id-type="pmid">35208939</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00232"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Munir</surname><given-names>S.</given-names></name>
<name><surname>Badshah</surname><given-names>S.L.</given-names></name>
<name><surname>Khan</surname><given-names>N.</given-names></name>
<name><surname>Ghani</surname><given-names>L.</given-names></name>
<name><surname>Poulson</surname><given-names>B.G.</given-names></name>
<name><surname>Emwas</surname><given-names>A.-H.</given-names></name>
<name><surname>Jaremko</surname><given-names>M.</given-names></name>
</person-group><article-title>Important Flavonoids and Their Role as a Therapeutic Agent</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>5243</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25225243</pub-id><pub-id pub-id-type="pmid">33187049</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00232"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Chemistry and Biological Activities of Flavonoids: An Overview</article-title><source>Sci. World J.</source><year>2013</year><volume>2013</volume><fpage>162750</fpage><pub-id pub-id-type="doi">10.1155/2013/162750</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-18-00232"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>U&#x000e7;ar</surname><given-names>K.</given-names></name>
<name><surname>G&#x000f6;kta&#x0015f;</surname><given-names>Z.</given-names></name>
</person-group><article-title>Biological Activities of Naringenin: A Narrative Review Based on in Vitro and in Vivo Studies</article-title><source>Nutr. Res.</source><year>2023</year><volume>119</volume><fpage>43</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2023.08.006</pub-id><pub-id pub-id-type="pmid">37738874</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00232"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>J.</given-names></name>
<name><surname>Wen</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Lan</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Dai</surname><given-names>X.</given-names></name>
<name><surname>Song</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Naringenin: A Flavanone with Anti-Inflammatory and Anti-Infective Properties</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>164</volume><elocation-id>114990</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114990</pub-id><pub-id pub-id-type="pmid">37315435</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00232"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>H.-S.</given-names></name>
<name><surname>Bhatia</surname><given-names>S.K.</given-names></name>
<name><surname>Gurav</surname><given-names>R.</given-names></name>
<name><surname>Choi</surname><given-names>T.-R.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>Y.-L.</given-names></name>
<name><surname>Han</surname><given-names>Y.-H.</given-names></name>
<name><surname>Park</surname><given-names>J.Y.</given-names></name>
<name><surname>Lee</surname><given-names>S.M.</given-names></name>
<name><surname>Park</surname><given-names>S.L.</given-names></name>
<etal/>
</person-group><article-title>Naringenin as an Antibacterial Reagent Controlling of Biofilm Formation and Fatty Acid Metabolism in MRSA</article-title><source>bioRxiv</source><year>2020</year><comment>bioRxiv:2020.03.08.983049</comment></element-citation></ref><ref id="B8-pharmaceuticals-18-00232"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duda-Madej</surname><given-names>A.</given-names></name>
<name><surname>Stecko</surname><given-names>J.</given-names></name>
<name><surname>Sobieraj</surname><given-names>J.</given-names></name>
<name><surname>Szyma&#x00144;ska</surname><given-names>N.</given-names></name>
<name><surname>Koz&#x00142;owska</surname><given-names>J.</given-names></name>
</person-group><article-title>Naringenin and Its Derivatives&#x02014;Health-Promoting Phytobiotic against Resistant Bacteria and Fungi in Humans</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>1628</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11111628</pub-id><pub-id pub-id-type="pmid">36421272</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00232"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.-H.</given-names></name>
<name><surname>Zeng</surname><given-names>X.-A.</given-names></name>
<name><surname>Wang</surname><given-names>M.-S.</given-names></name>
<name><surname>Brennan</surname><given-names>C.S.</given-names></name>
<name><surname>Gong</surname><given-names>D.</given-names></name>
</person-group><article-title>Modification of Membrane Properties and Fatty Acids Biosynthesis-Related Genes in Escherichia Coli and Staphylococcus Aureus: Implications for the Antibacterial Mechanism of Naringenin</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2018</year><volume>1860</volume><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2017.11.007</pub-id><pub-id pub-id-type="pmid">29138066</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00232"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vikram</surname><given-names>A.</given-names></name>
<name><surname>Jayaprakasha</surname><given-names>G.K.</given-names></name>
<name><surname>Jesudhasan</surname><given-names>P.R.</given-names></name>
<name><surname>Pillai</surname><given-names>S.D.</given-names></name>
<name><surname>Patil</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Suppression of Bacterial Cell&#x02013;Cell Signalling, Biofilm Formation and Type III Secretion System by Citrus Flavonoids</article-title><source>J. Appl. Microbiol.</source><year>2010</year><volume>109</volume><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2010.04677.x</pub-id><pub-id pub-id-type="pmid">20163489</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00232"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yue</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>F.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
</person-group><article-title>Influence of Naringenin on the Biofilm Formation of Streptococcus Mutans</article-title><source>J. Dent.</source><year>2018</year><volume>76</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.jdent.2018.04.013</pub-id><pub-id pub-id-type="pmid">29679633</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00232"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Dai</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>M.</given-names></name>
<name><surname>Tan</surname><given-names>W.</given-names></name>
<name><surname>Deng</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Inhibition of &#x003b1;-Toxin Production by Subinhibitory Concentrations of Naringenin Controls <italic toggle="yes">Staphylococcus Aureus</italic> Pneumonia</article-title><source>Fitoterapia</source><year>2013</year><volume>86</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2013.02.001</pub-id><pub-id pub-id-type="pmid">23425602</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00232"><label>13.</label><element-citation publication-type="webpage"><article-title>The Therapeutic Effects of Naringenin on Bronchial Pneumonia in Children&#x02014;Yao&#x02014;2021&#x02014;Pharmacology Research &#x00026; Perspectives&#x02014;Wiley Online Library</article-title><comment>Available online: <ext-link xlink:href="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.825" ext-link-type="uri">https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.825</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-22">(accessed on 22 October 2024)</date-in-citation></element-citation></ref><ref id="B14-pharmaceuticals-18-00232"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Yuan</surname><given-names>E.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Preparation and Physicochemical Properties of the Complex of Naringenin with Hydroxypropyl-&#x003b2;-Cyclodextrin</article-title><source>Molecules</source><year>2010</year><volume>15</volume><fpage>4401</fpage><lpage>4407</lpage><pub-id pub-id-type="doi">10.3390/molecules15064401</pub-id><pub-id pub-id-type="pmid">20657449</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00232"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salehi</surname><given-names>B.</given-names></name>
<name><surname>Fokou</surname><given-names>P.V.T.</given-names></name>
<name><surname>Sharifi-Rad</surname><given-names>M.</given-names></name>
<name><surname>Zucca</surname><given-names>P.</given-names></name>
<name><surname>Pezzani</surname><given-names>R.</given-names></name>
<name><surname>Martins</surname><given-names>N.</given-names></name>
<name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name>
</person-group><article-title>The Therapeutic Potential of Naringenin: A Review of Clinical Trials</article-title><source>Pharmaceuticals</source><year>2019</year><volume>12</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/ph12010011</pub-id><pub-id pub-id-type="pmid">30634637</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00232"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhia</surname><given-names>M.</given-names></name>
<name><surname>Motallebi</surname><given-names>M.</given-names></name>
<name><surname>Abadi</surname><given-names>B.</given-names></name>
<name><surname>Zarepour</surname><given-names>A.</given-names></name>
<name><surname>Pereira-Silva</surname><given-names>M.</given-names></name>
<name><surname>Saremnejad</surname><given-names>F.</given-names></name>
<name><surname>Santos</surname><given-names>A.C.</given-names></name>
<name><surname>Zarrabi</surname><given-names>A.</given-names></name>
<name><surname>Melero</surname><given-names>A.</given-names></name>
<name><surname>Jafari</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>Naringenin Nano-Delivery Systems and Their Therapeutic Applications</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>291</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13020291</pub-id><pub-id pub-id-type="pmid">33672366</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00232"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muankaew</surname><given-names>C.</given-names></name>
<name><surname>Loftsson</surname><given-names>T.</given-names></name>
</person-group><article-title>Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2018</year><volume>122</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12917</pub-id><pub-id pub-id-type="pmid">29024354</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00232"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pedotti</surname><given-names>S.</given-names></name>
<name><surname>Pistar&#x000e0;</surname><given-names>V.</given-names></name>
<name><surname>Cannav&#x000e0;</surname><given-names>C.</given-names></name>
<name><surname>Carbone</surname><given-names>C.</given-names></name>
<name><surname>Cilurzo</surname><given-names>F.</given-names></name>
<name><surname>Corsaro</surname><given-names>A.</given-names></name>
<name><surname>Puglisi</surname><given-names>G.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Synthesis and Physico-Chemical Characterization of a &#x003b2;-Cyclodextrin Conjugate for Sustained Release of Acyclovir</article-title><source>Carbohydr. Polym.</source><year>2015</year><volume>131</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2015.05.071</pub-id><pub-id pub-id-type="pmid">26256172</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00232"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Pastorello</surname><given-names>M.</given-names></name>
<name><surname>Pistar&#x000e0;</surname><given-names>V.</given-names></name>
<name><surname>Rescifina</surname><given-names>A.</given-names></name>
<name><surname>Margani</surname><given-names>F.</given-names></name>
<name><surname>Barbera</surname><given-names>V.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
<name><surname>Marino</surname><given-names>A.</given-names></name>
</person-group><article-title>Rutin/Sulfobutylether-&#x003b2;-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>233</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16020233</pub-id><pub-id pub-id-type="pmid">38399286</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00232"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Margani</surname><given-names>F.</given-names></name>
<name><surname>Barbera</surname><given-names>V.</given-names></name>
<name><surname>D&#x02019;Angelo</surname><given-names>V.</given-names></name>
<name><surname>German&#x000f2;</surname><given-names>M.P.</given-names></name>
<name><surname>Pistar&#x000e0;</surname><given-names>V.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Characterization and In Vivo Antiangiogenic Activity Evaluation of Morin-Based Cyclodextrin Inclusion Complexes</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2209</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15092209</pub-id><pub-id pub-id-type="pmid">37765179</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00232"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Cristiano</surname><given-names>M.C.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<name><surname>Celesti</surname><given-names>C.</given-names></name>
<name><surname>Iannazzo</surname><given-names>D.</given-names></name>
<name><surname>Pistar&#x000e0;</surname><given-names>V.</given-names></name>
<name><surname>Iraci</surname><given-names>N.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><elocation-id>1716</elocation-id><pub-id pub-id-type="doi">10.3390/biom12111716</pub-id><pub-id pub-id-type="pmid">36421730</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00232"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Mannino</surname><given-names>D.</given-names></name>
<name><surname>Celesti</surname><given-names>C.</given-names></name>
<name><surname>Bulzom&#x000ed;</surname><given-names>M.</given-names></name>
<name><surname>Iraci</surname><given-names>N.</given-names></name>
<name><surname>Vincenzo Giofr&#x000e8;</surname><given-names>S.</given-names></name>
<name><surname>Esposito</surname><given-names>E.</given-names></name>
<name><surname>Paterniti</surname><given-names>I.</given-names></name>
<name><surname>Anna Ventura</surname><given-names>C.</given-names></name>
</person-group><article-title>Randomly Methylated &#x003b2;-Cyclodextrin Improves Water&#x02014;Solubility, Cellular Protection and Mucosa Permeability of Idebenone</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>665</volume><fpage>124718</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124718</pub-id><pub-id pub-id-type="pmid">39288841</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00232"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Leggio</surname><given-names>L.</given-names></name>
<name><surname>Celesti</surname><given-names>C.</given-names></name>
<name><surname>Genovese</surname><given-names>F.</given-names></name>
<name><surname>Falcone</surname><given-names>M.</given-names></name>
<name><surname>Giofr&#x000e8;</surname><given-names>S.V.</given-names></name>
<name><surname>Iraci</surname><given-names>N.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Study of Host-Guest Interaction and In Vitro Neuroprotective Potential of Cinnamic Acid/Randomly Methylated &#x003b2;-Cyclodextrin Inclusion Complex</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>12778</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252312778</pub-id><pub-id pub-id-type="pmid">39684490</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00232"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tommasini</surname><given-names>S.</given-names></name>
<name><surname>Raneri</surname><given-names>D.</given-names></name>
<name><surname>Ficarra</surname><given-names>R.</given-names></name>
<name><surname>Calabr&#x000f2;</surname><given-names>M.L.</given-names></name>
<name><surname>Stancanelli</surname><given-names>R.</given-names></name>
<name><surname>Ficarra</surname><given-names>P.</given-names></name>
</person-group><article-title>Improvement in Solubility and Dissolution Rate of Flavonoids by Complexation with &#x003b2;-Cyclodextrin</article-title><source>J. Pharm. Biomed. Anal.</source><year>2004</year><volume>35</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(03)00647-2</pub-id><pub-id pub-id-type="pmid">15063470</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00232"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tommasini</surname><given-names>S.</given-names></name>
<name><surname>Calabr&#x000f2;</surname><given-names>M.L.</given-names></name>
<name><surname>Raneri</surname><given-names>D.</given-names></name>
<name><surname>Ficarra</surname><given-names>P.</given-names></name>
<name><surname>Ficarra</surname><given-names>R.</given-names></name>
</person-group><article-title>Combined Effect of pH and Polysorbates with Cyclodextrins on Solubilization of Naringenin</article-title><source>J. Pharm. Biomed. Anal.</source><year>2004</year><volume>36</volume><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2004.06.013</pub-id><pub-id pub-id-type="pmid">15496325</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00232"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shulman</surname><given-names>M.</given-names></name>
<name><surname>Cohen</surname><given-names>M.</given-names></name>
<name><surname>Soto-Gutierrez</surname><given-names>A.</given-names></name>
<name><surname>Yagi</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Goldwasser</surname><given-names>J.</given-names></name>
<name><surname>Lee-Parsons</surname><given-names>C.W.</given-names></name>
<name><surname>Benny-Ratsaby</surname><given-names>O.</given-names></name>
<name><surname>Yarmush</surname><given-names>M.L.</given-names></name>
<name><surname>Nahmias</surname><given-names>Y.</given-names></name>
</person-group><article-title>Enhancement of Naringenin Bioavailability by Complexation with Hydroxypropoyl-&#x003b2;-Cyclodextrin</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e18033</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018033</pub-id><pub-id pub-id-type="pmid">21494673</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00232"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Begines</surname><given-names>B.</given-names></name>
<name><surname>Ortiz</surname><given-names>T.</given-names></name>
<name><surname>P&#x000e9;rez-Aranda Redondo</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>G.</given-names></name>
<name><surname>Merinero de Los Santos</surname><given-names>M.</given-names></name>
<name><surname>Arias</surname><given-names>F.</given-names></name>
<name><surname>Alcudia</surname><given-names>A.</given-names></name>
</person-group><article-title>Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>1403</elocation-id><pub-id pub-id-type="doi">10.3390/nano10071403</pub-id><pub-id pub-id-type="pmid">32707641</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00232"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Scala</surname><given-names>A.</given-names></name>
<name><surname>Celesti</surname><given-names>C.</given-names></name>
<name><surname>Lambertsen Larsen</surname><given-names>K.</given-names></name>
<name><surname>Genovese</surname><given-names>F.</given-names></name>
<name><surname>Bongiorno</surname><given-names>C.</given-names></name>
<name><surname>Leggio</surname><given-names>L.</given-names></name>
<name><surname>Iraci</surname><given-names>N.</given-names></name>
<name><surname>Mazzaglia</surname><given-names>A.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Amphiphilic Cyclodextrin Nanoparticles as Delivery System for Idebenone: A Preformulation Study</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>3023</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28073023</pub-id><pub-id pub-id-type="pmid">37049785</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00232"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>d&#x02019;Avanzo</surname><given-names>N.</given-names></name>
<name><surname>Mancuso</surname><given-names>A.</given-names></name>
<name><surname>De Gaetano</surname><given-names>A.</given-names></name>
<name><surname>Paladini</surname><given-names>G.</given-names></name>
<name><surname>Caridi</surname><given-names>F.</given-names></name>
<name><surname>Venuti</surname><given-names>V.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Chitosan/Cyclodextrin Nanospheres for Potential Nose-to-Brain Targeting of Idebenone</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>1206</elocation-id><pub-id pub-id-type="doi">10.3390/ph15101206</pub-id><pub-id pub-id-type="pmid">36297318</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00232"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cannav&#x000e0;</surname><given-names>C.</given-names></name>
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Stancanelli</surname><given-names>R.</given-names></name>
<name><surname>Venuti</surname><given-names>V.</given-names></name>
<name><surname>Paladini</surname><given-names>G.</given-names></name>
<name><surname>Caridi</surname><given-names>F.</given-names></name>
<name><surname>Ghica</surname><given-names>C.</given-names></name>
<name><surname>Crupi</surname><given-names>V.</given-names></name>
<name><surname>Majolino</surname><given-names>D.</given-names></name>
<name><surname>Ferlazzo</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Chitosan-Hyaluronan Nanoparticles for Vinblastine Sulfate Delivery: Characterization and Internalization Studies on K-562 Cells</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>942</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14050942</pub-id><pub-id pub-id-type="pmid">35631528</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00232"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cristiano</surname><given-names>M.C.</given-names></name>
<name><surname>Mancuso</surname><given-names>A.</given-names></name>
<name><surname>Fresta</surname><given-names>M.</given-names></name>
<name><surname>Torella</surname><given-names>D.</given-names></name>
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Ventura</surname><given-names>C.A.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
</person-group><article-title>Topical Unsaturated Fatty Acid Vesicles Improve Antioxidant Activity of Ammonium Glycyrrhizinate</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>548</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13040548</pub-id><pub-id pub-id-type="pmid">33919824</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00232"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elmowafy</surname><given-names>M.</given-names></name>
<name><surname>Shalaby</surname><given-names>K.</given-names></name>
<name><surname>Elkomy</surname><given-names>M.H.</given-names></name>
<name><surname>Alsaidan</surname><given-names>O.A.</given-names></name>
<name><surname>Gomaa</surname><given-names>H.A.M.</given-names></name>
<name><surname>Abdelgawad</surname><given-names>M.A.</given-names></name>
<name><surname>Mostafa</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges</article-title><source>Polymers</source><year>2023</year><volume>15</volume><elocation-id>1123</elocation-id><pub-id pub-id-type="doi">10.3390/polym15051123</pub-id><pub-id pub-id-type="pmid">36904364</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00232"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>H.T.</given-names></name>
<name><surname>Hensel</surname><given-names>A.</given-names></name>
<name><surname>Goycoolea</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Chitosan/Cyclodextrin Surface-Adsorbed Naringenin-Loaded Nanocapsules Enhance Bacterial Quorum Quenching and Anti-Biofilm Activities</article-title><source>Colloids Surf. B Biointerfaces</source><year>2022</year><volume>211</volume><elocation-id>112281</elocation-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2021.112281</pub-id><pub-id pub-id-type="pmid">34952287</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00232"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nouri</surname><given-names>Z.</given-names></name>
<name><surname>Sajadimajd</surname><given-names>S.</given-names></name>
<name><surname>Hoseinzadeh</surname><given-names>L.</given-names></name>
<name><surname>Bahrami</surname><given-names>G.</given-names></name>
<name><surname>Arkan</surname><given-names>E.</given-names></name>
<name><surname>Moradi</surname><given-names>S.</given-names></name>
<name><surname>Abdi</surname><given-names>F.</given-names></name>
<name><surname>Farzaei</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Neuroprotective Effect of Naringenin-Loaded Solid Lipid Nanoparticles against Streptozocin-Induced Neurotoxicity through Autophagy Blockage</article-title><source>J. Food Biochem.</source><year>2022</year><volume>46</volume><elocation-id>e14408</elocation-id><pub-id pub-id-type="doi">10.1111/jfbc.14408</pub-id><pub-id pub-id-type="pmid">36129161</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00232"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Md</surname><given-names>S.</given-names></name>
<name><surname>Alhakamy</surname><given-names>N.A.</given-names></name>
<name><surname>Aldawsari</surname><given-names>H.M.</given-names></name>
<name><surname>Asfour</surname><given-names>H.Z.</given-names></name>
</person-group><article-title>Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-to-Brain Delivery</article-title><source>Brain Sci.</source><year>2019</year><volume>9</volume><elocation-id>275</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci9100275</pub-id><pub-id pub-id-type="pmid">31618942</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00232"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranjbar</surname><given-names>S.</given-names></name>
<name><surname>Emamjomeh</surname><given-names>A.</given-names></name>
<name><surname>Sharifi</surname><given-names>F.</given-names></name>
<name><surname>Zarepour</surname><given-names>A.</given-names></name>
<name><surname>Aghaabbasi</surname><given-names>K.</given-names></name>
<name><surname>Dehshahri</surname><given-names>A.</given-names></name>
<name><surname>Sepahvand</surname><given-names>A.M.</given-names></name>
<name><surname>Zarrabi</surname><given-names>A.</given-names></name>
<name><surname>Beyzaei</surname><given-names>H.</given-names></name>
<name><surname>Zahedi</surname><given-names>M.M.</given-names></name>
<etal/>
</person-group><article-title>Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1944</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15071944</pub-id><pub-id pub-id-type="pmid">37514130</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00232"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhiman</surname><given-names>N.</given-names></name>
<name><surname>Awasthi</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>B.</given-names></name>
<name><surname>Kharkwal</surname><given-names>H.</given-names></name>
<name><surname>Kulkarni</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Lipid Nanoparticles as Carriers for Bioactive Delivery</article-title><source>Front. Chem.</source><year>2021</year><volume>9</volume><elocation-id>580118</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2021.580118</pub-id><pub-id pub-id-type="pmid">33981670</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00232"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>R.H.</given-names></name>
<name><surname>M&#x000e4;der</surname><given-names>K.</given-names></name>
<name><surname>Gohla</surname><given-names>S.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery&#x02014;A Review of the State of the Art</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2000</year><volume>50</volume><fpage>161</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/S0939-6411(00)00087-4</pub-id><pub-id pub-id-type="pmid">10840199</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00232"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Cristiano</surname><given-names>M.C.</given-names></name>
<name><surname>Venuti</surname><given-names>V.</given-names></name>
<name><surname>Crupi</surname><given-names>V.</given-names></name>
<name><surname>Majolino</surname><given-names>D.</given-names></name>
<name><surname>Paladini</surname><given-names>G.</given-names></name>
<name><surname>Acri</surname><given-names>G.</given-names></name>
<name><surname>Testagrossa</surname><given-names>B.</given-names></name>
<name><surname>Irrera</surname><given-names>A.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Rutin-Loaded Solid Lipid Nanoparticles: Characterization and In Vitro Evaluation</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>1039</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26041039</pub-id><pub-id pub-id-type="pmid">33669321</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00232"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paliwal</surname><given-names>R.</given-names></name>
<name><surname>Paliwal</surname><given-names>S.R.</given-names></name>
<name><surname>Kenwat</surname><given-names>R.</given-names></name>
<name><surname>Kurmi</surname><given-names>B.D.</given-names></name>
<name><surname>Sahu</surname><given-names>M.K.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles: A Review on Recent Perspectives and Patents</article-title><source>Expert Opin. Ther. Pat.</source><year>2020</year><volume>30</volume><fpage>179</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1080/13543776.2020.1720649</pub-id><pub-id pub-id-type="pmid">32003260</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00232"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gaetano</surname><given-names>F.</given-names></name>
<name><surname>Celesti</surname><given-names>C.</given-names></name>
<name><surname>Paladini</surname><given-names>G.</given-names></name>
<name><surname>Venuti</surname><given-names>V.</given-names></name>
<name><surname>Cristiano</surname><given-names>M.C.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<name><surname>Iannazzo</surname><given-names>D.</given-names></name>
<name><surname>Strano</surname><given-names>V.</given-names></name>
<name><surname>Gueli</surname><given-names>A.M.</given-names></name>
<name><surname>Tommasini</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Solid Lipid Nanoparticles Containing Morin: Preparation, Characterization, and Ex Vivo Permeation Studies</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1605</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15061605</pub-id><pub-id pub-id-type="pmid">37376054</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00232"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghasemiyeh</surname><given-names>P.</given-names></name>
<name><surname>Mohammadi-Samani</surname><given-names>S.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Novel Drug Delivery Systems: Applications, Advantages and Disadvantages</article-title><source>Res. Pharm. Sci.</source><year>2018</year><volume>13</volume><fpage>288</fpage><pub-id pub-id-type="doi">10.4103/1735-5362.235156</pub-id><pub-id pub-id-type="pmid">30065762</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00232"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganesan</surname><given-names>P.</given-names></name>
<name><surname>Narayanasamy</surname><given-names>D.</given-names></name>
</person-group><article-title>Lipid Nanoparticles: Different Preparation Techniques, Characterization, Hurdles, and Strategies for the Production of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Oral Drug Delivery</article-title><source>Sustain. Chem. Pharm.</source><year>2017</year><volume>6</volume><fpage>37</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.scp.2017.07.002</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-18-00232"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pour</surname><given-names>P.M.</given-names></name>
<name><surname>Nouri</surname><given-names>Z.</given-names></name>
<name><surname>Ghasemi</surname><given-names>D.</given-names></name>
<name><surname>Sajadimajd</surname><given-names>S.</given-names></name>
<name><surname>Farzaei</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Cytotoxic Impact of Naringenin-Loaded Solid Lipid Nanoparticles on RIN5F Pancreatic &#x003b2; Cells via Autophagy Blockage</article-title><source>Recent Patents Drug Deliv. Formul.</source><year>2024</year><volume>18</volume><fpage>304</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.2174/0126673878297658240804192222</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-18-00232"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mani</surname><given-names>M.</given-names></name>
<name><surname>Balasubramanian</surname><given-names>S.</given-names></name>
<name><surname>Manikandan</surname><given-names>K.R.</given-names></name>
<name><surname>Kulandaivel</surname><given-names>B.</given-names></name>
</person-group><article-title>Neuroprotective Potential of Naringenin-Loaded Solid-Lipid Nanoparticles against Rotenone-Induced Parkinson&#x02019;s Disease Model</article-title><source>J. Appl. Pharm. Sci.</source><year>2021</year><volume>11</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.7324/JAPS.2021.110203</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-18-00232"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munir</surname><given-names>A.</given-names></name>
<name><surname>Muhammad</surname><given-names>F.</given-names></name>
<name><surname>Zaheer</surname><given-names>Y.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Iqbal</surname><given-names>M.</given-names></name>
<name><surname>Rehman</surname><given-names>M.</given-names></name>
<name><surname>Munir</surname><given-names>M.U.</given-names></name>
<name><surname>Akhtar</surname><given-names>B.</given-names></name>
<name><surname>Webster</surname><given-names>T.</given-names></name>
<name><surname>Sharif</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Synthesis of Naringenin Loaded Lipid Based Nanocarriers and Their In-Vivo Therapeutic Potential in a Rheumatoid Arthritis Model</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>66</volume><fpage>102854</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102854</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-18-00232"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>Y.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>Naringenin-Loaded Solid Lipid Nanoparticles: Preparation, Controlled Delivery, Cellular Uptake, and Pulmonary Pharmacokinetics</article-title><source>Drug Des. Dev. Ther.</source><year>2016</year><volume>10</volume><fpage>911</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S97738</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-18-00232"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souto</surname><given-names>E.B.</given-names></name>
<name><surname>Mehnert</surname><given-names>W.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Polymorphic Behaviour of Compritol&#x000ae;888 ATO as Bulk Lipid and as SLN and NLC</article-title><source>J. Microencapsul.</source><year>2006</year><volume>23</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1080/02652040600612439</pub-id><pub-id pub-id-type="pmid">16854817</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00232"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aburahma</surname><given-names>M.H.</given-names></name>
<name><surname>Badr-Eldin</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Compritol 888 ATO: A Multifunctional Lipid Excipient in Drug Delivery Systems and Nanopharmaceuticals</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>1865</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.935335</pub-id><pub-id pub-id-type="pmid">25152197</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00232"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Md</surname><given-names>S.</given-names></name>
<name><surname>Gan</surname><given-names>S.Y.</given-names></name>
<name><surname>Haw</surname><given-names>Y.H.</given-names></name>
<name><surname>Ho</surname><given-names>C.L.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Choudhury</surname><given-names>H.</given-names></name>
</person-group><article-title>In Vitro Neuroprotective Effects of Naringenin Nanoemulsion against &#x003b2;-Amyloid Toxicity through the Regulation of Amyloidogenesis and Tau Phosphorylation</article-title><source>Int. J. Biol. Macromol.</source><year>2018</year><volume>118</volume><fpage>1211</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.06.190</pub-id><pub-id pub-id-type="pmid">30001606</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00232"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akrawi</surname><given-names>S.H.</given-names></name>
<name><surname>Gorain</surname><given-names>B.</given-names></name>
<name><surname>Nair</surname><given-names>A.B.</given-names></name>
<name><surname>Choudhury</surname><given-names>H.</given-names></name>
<name><surname>Pandey</surname><given-names>M.</given-names></name>
<name><surname>Shah</surname><given-names>J.N.</given-names></name>
<name><surname>Venugopala</surname><given-names>K.N.</given-names></name>
</person-group><article-title>Development and Optimization of Naringenin-Loaded Chitosan-Coated Nanoemulsion for Topical Therapy in Wound Healing</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12090893</pub-id><pub-id pub-id-type="pmid">32962195</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00232"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sahu</surname><given-names>A.</given-names></name>
<name><surname>Sahu</surname><given-names>G.K.</given-names></name>
<name><surname>Dash</surname><given-names>D.</given-names></name>
<name><surname>Mishra</surname><given-names>S.P.</given-names></name>
<name><surname>Mishra</surname><given-names>K.</given-names></name>
<name><surname>Kashyap</surname><given-names>P.</given-names></name>
<name><surname>Jain</surname><given-names>V.</given-names></name>
</person-group><article-title>Assessment of in Vitro Naringenin Release from Solid Lipid Nanoparticles and Kinetic Model Profiling: Applied Ultraviolet-Visible Spectrophotometer</article-title><source>Indian Drugs</source><year>2017</year><volume>54</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.53879/id.54.11.11035</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-18-00232"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Sheng</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Naringenin Loaded Multifunctional Nanoparticles to Enhance the Chemotherapeutic Efficacy in Hepatic Fibrosis</article-title><source>Biomed. Microdevices</source><year>2020</year><volume>22</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1007/s10544-020-00524-1</pub-id><pub-id pub-id-type="pmid">32955605</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00232"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wani</surname><given-names>F.A.</given-names></name>
<name><surname>Behera</surname><given-names>K.</given-names></name>
<name><surname>Patel</surname><given-names>R.</given-names></name>
</person-group><article-title>Amphiphilic Micelles as Superior Nanocarriers in Drug Delivery: From Current Preclinical Surveys to Structural Frameworks</article-title><source>ChemistrySelect</source><year>2022</year><volume>7</volume><fpage>e202201928</fpage><pub-id pub-id-type="doi">10.1002/slct.202201928</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-18-00232"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>M.</given-names></name>
<name><surname>Acet</surname><given-names>&#x000d6;.</given-names></name>
<name><surname>Yetkin</surname><given-names>D.</given-names></name>
<name><surname>Acet</surname><given-names>B.&#x000d6;.</given-names></name>
<name><surname>Karakoc</surname><given-names>V.</given-names></name>
<name><surname>Odabas&#x00131;</surname><given-names>M.</given-names></name>
</person-group><article-title>Anti-Cancer Activity of Naringenin Loaded Smart Polymeric Nanoparticles in Breast Cancer</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>74</volume><fpage>103552</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103552</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-18-00232"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>L.</given-names></name>
<name><surname>An</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
</person-group><article-title>Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers</article-title><source>J. Drug Deliv.</source><year>2011</year><volume>2011</volume><fpage>370308</fpage><pub-id pub-id-type="doi">10.1155/2011/370308</pub-id><pub-id pub-id-type="pmid">21845225</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00232"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Mechanism of sustained-action medication. theoretical analysis of rate of release of solid drugs dispersed in solid matrices</article-title><source>J. Pharm. Sci.</source><year>1963</year><volume>52</volume><fpage>1145</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1002/jps.2600521210</pub-id><pub-id pub-id-type="pmid">14088963</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00232"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siepmann</surname><given-names>J.</given-names></name>
<name><surname>Siepmann</surname><given-names>F.</given-names></name>
</person-group><article-title>Mathematical Modeling of Drug Release from Lipid Dosage Forms</article-title><source>Int. J. Pharm.</source><year>2011</year><volume>418</volume><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.07.015</pub-id><pub-id pub-id-type="pmid">21802501</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00232"><label>59.</label><element-citation publication-type="gov"><article-title>Modeling and Comparison of Dissolution Profiles&#x02014;PubMed</article-title><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/11297896/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/11297896/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-08">(accessed on 8 March 2024)</date-in-citation></element-citation></ref><ref id="B60-pharmaceuticals-18-00232"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parhi</surname><given-names>R.</given-names></name>
<name><surname>Suresh</surname><given-names>P.</given-names></name>
</person-group><article-title>Production of Solid Lipid Nanoparticles-Drug Loading and Release Mechanism</article-title><source>J. Chem. Pharm. Res.</source><year>2010</year><volume>2</volume><fpage>211</fpage><lpage>227</lpage></element-citation></ref><ref id="B61-pharmaceuticals-18-00232"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>V.</given-names></name>
<name><surname>Bansal</surname><given-names>K.K.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Yadav</surname><given-names>N.</given-names></name>
<name><surname>Thakur</surname><given-names>S.</given-names></name>
<name><surname>Sudhakar</surname><given-names>K.</given-names></name>
<name><surname>Rosenholm</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10040191</pub-id><pub-id pub-id-type="pmid">30340327</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00232"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celiz</surname><given-names>G.</given-names></name>
<name><surname>Suarez</surname><given-names>S.A.</given-names></name>
<name><surname>Arias</surname><given-names>A.</given-names></name>
<name><surname>Molina</surname><given-names>J.</given-names></name>
<name><surname>Brondino</surname><given-names>C.D.</given-names></name>
<name><surname>Doctorovich</surname><given-names>F.</given-names></name>
</person-group><article-title>Synthesis, Structural Elucidation and Antiradical Activity of a Copper (II) Naringenin Complex</article-title><source>Biometals</source><year>2019</year><volume>32</volume><fpage>595</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1007/s10534-019-00187-3</pub-id><pub-id pub-id-type="pmid">30911923</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00232"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unsalan</surname><given-names>O.</given-names></name>
<name><surname>Gulluoglu</surname><given-names>M.</given-names></name>
</person-group><article-title>FT-Raman and FT-IR Spectral and Quantum Chemical Studies on Some Flavonoid Derivatives: Baicalein and Naringenin</article-title><source>J. Raman Spectrosc.</source><year>2009</year><volume>40</volume><fpage>562</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1002/jrs.2166</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-18-00232"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.-H.</given-names></name>
<name><surname>Wang</surname><given-names>M.-S.</given-names></name>
<name><surname>Zeng</surname><given-names>X.-A.</given-names></name>
<name><surname>Xu</surname><given-names>X.-M.</given-names></name>
<name><surname>Brennan</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Membrane and Genomic DNA Dual-Targeting of Citrus Flavonoid Naringenin against Staphylococcus Aureus</article-title><source>Integr. Biol.</source><year>2017</year><volume>9</volume><fpage>820</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1039/C7IB00095B</pub-id><pub-id pub-id-type="pmid">28862705</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00232"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>G.</given-names></name>
<name><surname>Mehta</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Developments of Polysorbate (Tween) Based Microemulsions: Preclinical Drug Delivery, Toxicity and Antimicrobial Applications</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>529</volume><fpage>134</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.06.059</pub-id><pub-id pub-id-type="pmid">28642203</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-18-00232"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>C.K.</given-names></name>
<name><surname>Kjems</surname><given-names>J.</given-names></name>
<name><surname>Mygind</surname><given-names>T.</given-names></name>
<name><surname>Snabe</surname><given-names>T.</given-names></name>
<name><surname>Meyer</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Effects of Tween 80 on Growth and Biofilm Formation in Laboratory Media</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>1878</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.01878</pub-id><pub-id pub-id-type="pmid">27920774</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00232"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menberu</surname><given-names>M.A.</given-names></name>
<name><surname>Hayes</surname><given-names>A.J.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Psaltis</surname><given-names>A.J.</given-names></name>
<name><surname>Wormald</surname><given-names>P.-J.</given-names></name>
<name><surname>Vreugde</surname><given-names>S.</given-names></name>
</person-group><article-title>Tween 80 and Its Derivative Oleic Acid Promote the Growth of Corynebacterium Accolens and Inhibit Staphylococcus Aureus Clinical Isolates</article-title><source>Int. Forum Allergy Rhinol.</source><year>2021</year><volume>11</volume><fpage>810</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1002/alr.22730</pub-id><pub-id pub-id-type="pmid">33156566</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-18-00232"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wen</surname><given-names>Q.-H.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Zhao</surname><given-names>S.-Q.</given-names></name>
<name><surname>Chen</surname><given-names>B.-R.</given-names></name>
<name><surname>Zeng</surname><given-names>X.-A.</given-names></name>
</person-group><article-title>Inhibition of Biofilm Formation of Foodborne Staphylococcus Aureus by the Citrus Flavonoid Naringenin</article-title><source>Foods</source><year>2021</year><volume>10</volume><elocation-id>2614</elocation-id><pub-id pub-id-type="doi">10.3390/foods10112614</pub-id><pub-id pub-id-type="pmid">34828898</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00232"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueda</surname><given-names>Y.</given-names></name>
<name><surname>Mashima</surname><given-names>K.</given-names></name>
<name><surname>Miyazaki</surname><given-names>M.</given-names></name>
<name><surname>Hara</surname><given-names>S.</given-names></name>
<name><surname>Takata</surname><given-names>T.</given-names></name>
<name><surname>Kamimura</surname><given-names>H.</given-names></name>
<name><surname>Takagi</surname><given-names>S.</given-names></name>
<name><surname>Jimi</surname><given-names>S.</given-names></name>
</person-group><article-title>Inhibitory Effects of Polysorbate 80 on MRSA Biofilm Formed on Different Substrates Including Dermal Tissue</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>3128</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39997-3</pub-id><pub-id pub-id-type="pmid">30816342</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00232"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butani</surname><given-names>D.</given-names></name>
<name><surname>Yewale</surname><given-names>C.</given-names></name>
<name><surname>Misra</surname><given-names>A.</given-names></name>
</person-group><article-title>Topical Amphotericin B Solid Lipid Nanoparticles: Design and Development</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>139</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.07.032</pub-id><pub-id pub-id-type="pmid">26700229</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00232"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordillo-Galeano</surname><given-names>A.</given-names></name>
<name><surname>Mora-Huertas</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review Emphasizing on Particle Structure and Drug Release</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>133</volume><fpage>285</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.10.017</pub-id><pub-id pub-id-type="pmid">30463794</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00232"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jha</surname><given-names>D.K.</given-names></name>
<name><surname>Shah</surname><given-names>D.S.</given-names></name>
<name><surname>Talele</surname><given-names>S.R.</given-names></name>
<name><surname>Amin</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Correlation of Two Validated Methods for the Quantification of Naringenin in Its Solid Dispersion: HPLC and UV Spectrophotometric Methods</article-title><source>SN Appl. Sci.</source><year>2020</year><volume>2</volume><fpage>698</fpage><pub-id pub-id-type="doi">10.1007/s42452-020-2536-3</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-18-00232"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Burgess</surname><given-names>D.J.</given-names></name>
</person-group><article-title>In Vitro Dissolution Testing Strategies for Nanoparticulate Drug Delivery Systems: Recent Developments and Challenges</article-title><source>Drug Deliv. Transl. Res.</source><year>2013</year><volume>3</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1007/s13346-013-0129-z</pub-id><pub-id pub-id-type="pmid">24069580</pub-id>
</element-citation></ref><ref id="B74-pharmaceuticals-18-00232"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
</person-group><article-title>In Vitro Dissolution Considerations Associated with Nano Drug Delivery Systems (NDDS)</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2021</year><volume>13</volume><elocation-id>e1732</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1732</pub-id><pub-id pub-id-type="pmid">34132050</pub-id>
</element-citation></ref><ref id="B75-pharmaceuticals-18-00232"><label>75.</label><element-citation publication-type="webpage"><article-title>M100Ed34|Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition</article-title><comment>Available online: <ext-link xlink:href="https://clsi.org/standards/products/microbiology/documents/m100/" ext-link-type="uri">https://clsi.org/standards/products/microbiology/documents/m100/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-27">(accessed on 27 March 2024)</date-in-citation></element-citation></ref><ref id="B76-pharmaceuticals-18-00232"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nostro</surname><given-names>A.</given-names></name>
<name><surname>Roccaro</surname><given-names>A.S.</given-names></name>
<name><surname>Bisignano</surname><given-names>G.</given-names></name>
<name><surname>Marino</surname><given-names>A.</given-names></name>
<name><surname>Cannatelli</surname><given-names>M.A.</given-names></name>
<name><surname>Pizzimenti</surname><given-names>F.C.</given-names></name>
<name><surname>Cioni</surname><given-names>P.L.</given-names></name>
<name><surname>Procopio</surname><given-names>F.</given-names></name>
<name><surname>Blanco</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Effects of Oregano, Carvacrol and Thymol on Staphylococcus Aureus and Staphylococcus Epidermidis Biofilms</article-title><source>J. Med. Microbiol.</source><year>2007</year><volume>56</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46804-0</pub-id><pub-id pub-id-type="pmid">17374894</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00232"><label>77.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bonferroni</surname><given-names>C.E.</given-names></name>
</person-group><source>Teoria Statistica Delle Classi e Calcolo Delle Probabilit&#x000e0;</source><publisher-name>Seeber</publisher-name><publisher-loc>Castelbello-Ciardes, Italy</publisher-loc><year>1936</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00232-f001"><label>Figure 1</label><caption><p>In vitro release profiles of NRG<sub>10</sub>-SLNs (black squares), comparative to free NRG (red circles). The results are expressed as mean values from three different experiments and three different batches &#x000b1; S.D. If bars are not visible, they are within the symbol. All values for the NRG<sub>10</sub>-SLNs (excluding 0, 168, and 240 h) are statistically significant compared to the free RTN data (<italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00232-f002"><label>Figure 2</label><caption><p>TGA thermograms (<bold>a</bold>), DSC analysis (<bold>b</bold>), and X-ray diffraction patterns (<bold>c</bold>) of COM (pink line), NRG (red line), empty SLNs (blue line), NRG+SLNs physical mixture (green line), and NRG<sub>10</sub>-SLNs (black line).</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00232-f003"><label>Figure 3</label><caption><p>(<bold>a</bold>) Structure and atomic numbering of NRG. In particular, the positions of the carbon atoms are represented in gray, and those of the oxygen atoms are represented in red. (<bold>b</bold>) The experimental &#x000b5;-Raman spectrum of NRG. (<bold>c</bold>) Experimental &#x000b5;-Raman spectra, in the 1500&#x02013;1700 cm<sup>&#x02212;</sup><sup>1</sup> wavenumber range, respectively associated with NRG (black line) and NRG<sub>10</sub>-SLNs (red line). In the inset, the experimental &#x000b5;-Raman spectrum of empty SLN is reported (pink line), evidencing the 1500&#x02013;1700 cm<sup>&#x02212;1</sup> wavenumber range, free of vibrational contributions from the solid&#x02013;lipid matrix.</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00232-f004"><label>Figure 4</label><caption><p>STEM images of lyophilized NRG<sub>10</sub>-SLNs before (<bold>a</bold>) and after (<bold>b</bold>) redispersion. The bar width in the panels indicates the size.</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00232-f005"><label>Figure 5</label><caption><p>Inhibition of the metabolic activity of <italic toggle="yes">S. aureus</italic> ATCC 6538 cells after the addition of triphenyl tetrazolium chloride (TTC) 0.125% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>).</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00232-f006"><label>Figure 6</label><caption><p>Effects of different concentrations (from 0.5&#x000d7; MIC to 0.125&#x000d7; MIC) of NRG10-SLNs, free NRG, and empty SLNs on biofilm formation in <italic toggle="yes">S. aureus</italic> ATCC 6538 and <italic toggle="yes">S. aureus</italic> ATCC 43300 (MRSA). Data are presented as mean &#x000b1; SD, * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01 vs. control.</p></caption><graphic xlink:href="pharmaceuticals-18-00232-g006" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00232-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00232-t001_Table 1</object-id><label>Table 1</label><caption><p>Encapsulation parameters (E.E. %, D.C. %) and Yield % of NRG-SLNs prepared with different theoretical amounts of NRG (namely, NRG<sub>x</sub>-SLNs, with x = 1, &#x02026; 10%).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Yield % &#x000b1; S.D.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E.E. % &#x000b1; S.D.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">D.C. % &#x000b1; S.D.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Empty SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">48.1 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>1</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">52.3 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">89.2 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37 &#x000b1; 0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>2</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">54.8 &#x000b1; 3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">92.5 &#x000b1; 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 &#x000b1; 0.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>3</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">58.1 &#x000b1; 7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">95.6 &#x000b1; 1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 &#x000b1; 0.16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>4</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">46.8 &#x000b1; 2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">93.8 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.72 &#x000b1; 2.40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>5</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">54.0 &#x000b1; 3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">94.6 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88 &#x000b1; 3.25</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>6</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">52.5 &#x000b1; 6.2</td><td align="center" valign="middle" rowspan="1" colspan="1">94.4 &#x000b1; 2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.65 &#x000b1; 1.58</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>7</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">48.8 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">92.5 &#x000b1; 4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.80 &#x000b1; 0.80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>8</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">48.6 &#x000b1; 6.6</td><td align="center" valign="middle" rowspan="1" colspan="1">92.7 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.26 &#x000b1; 2.13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRG<sub>9</sub>-SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">56.2 &#x000b1; 5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">94.2 &#x000b1; 4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.20 &#x000b1; 1.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRG<sub>10</sub>-SLNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.5 &#x000b1; 4.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.9 &#x000b1; 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.11 &#x000b1; 0.20</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00232-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00232-t002_Table 2</object-id><label>Table 2</label><caption><p>Hydrodynamic diameters (D<sub>H</sub>), polydispersity index (PDI), and zeta potential (&#x003b6;) values in empty SLNs and NRG10-SLNs samples, before and after lyophilization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">D<sub>H</sub> (nm) &#x000b1; S.D.</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PDI (%) &#x000b1; S.D.</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">&#x003b6; (mV) &#x000b1; S.D.</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Empty SLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">54.4 &#x000b1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">50.2 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;30.5 &#x000b1; 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;29.3 &#x000b1; 1.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRG<sub>10</sub>-SLNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.8 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.8 &#x000b1; 6.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;30.3 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;30.5 &#x000b1; 2.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00232-t003"><object-id pub-id-type="pii">pharmaceuticals-18-00232-t003_Table 3</object-id><label>Table 3</label><caption><p>Hydrodynamic diameter (D<sub>H</sub>), polydispersity index (PDI), and zeta potential (&#x003b6;) values in the redispersed NRG<sub>10</sub>-SLNs formulation at different conditions of light and temperature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Day</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">4&#x000b0; C</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">25&#x000b0; C in the Daylight</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">25 &#x000b0; C in the Dark</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D<sub>H</sub> (nm) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDI (%) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b6; (mV) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D<sub>H</sub> (nm) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDI (%) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b6; (mV) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D<sub>H</sub> (nm) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDI (%) &#x000b1; S.D.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b6; (mV) &#x000b1; S.D.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.8 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;30.3 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.8 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;30.3 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.8 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;30.3 &#x000b1; 0.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.6 &#x000b1; 3.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;28.1 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.4 &#x000b1; 3.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;31.2 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.4 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;29.2 &#x000b1; 0.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.4 &#x000b1; 1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;27.8 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.6 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;29.9 &#x000b1; 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.4 &#x000b1; 6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;28.6 &#x000b1; 1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.5 &#x000b1; 9.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14 &#x000b1; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;24.5 &#x000b1; 0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.3 &#x000b1; 3.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;28.9 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.5 &#x000b1; 2.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;27.9 &#x000b1; 2.9</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00232-t004"><object-id pub-id-type="pii">pharmaceuticals-18-00232-t004_Table 4</object-id><label>Table 4</label><caption><p>Regression coefficient (R<sup>2</sup>), rate constant (K<sub>0</sub>, K<sub>1,</sub> and K<sub>H</sub> for zero-order, first-order, and Higuchi model, respectively), and transport exponent (n) of Korsmeyer-Peppas model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Zero-Order </th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">First-Order</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Higuchi</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Korsmeyer-Peppas </th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K<sub>0</sub> (d<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K<sub>1</sub> (d<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K<sub>H</sub> (d<sup>&#x02212;1/2</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRG<sub>10</sub>-SLNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5665</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0275</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9535</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.0534</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5764</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00232-t005"><object-id pub-id-type="pii">pharmaceuticals-18-00232-t005_Table 5</object-id><label>Table 5</label><caption><p>Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of free NRG, NRG<sub>10</sub>-SLNs, and empty SLNs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Strains</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">NRG<sub>10</sub>-SLNs </th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">NRG</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Empty SLNs</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBC</th></tr><tr><th colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">mg/mL</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> ATCC 6538</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> (MRSA)ATCC 43300 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic> ATCC 10536</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. aeruginosa</italic> ATCC 9027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1</td></tr></tbody></table></table-wrap></floats-group></article>